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METHODS AND COMPOSITIONS FOR
VACCNATION OF ANIMALS WITH PRRSV
ANTIGENS WITH IMPROVED
IMMUNOGENICITY
CROSS-REFERENCE TO RELATED
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This application claims priority to U.S. Provisional Patent
Application No. 60/712.357, filed on Aug. 30, 2005.

10

STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH ORDEVELOPMENT

This invention was made with Government Support under a
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from the U.S. Department of Agriculture and under a
National Institute of Health COBRE program of the National
Center for Research Resources Project #P20RR 15636. The
government has certain rights to this invention.
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APPENDIX

Not Applicable
25

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates generally to compositions compris
ing Porcine Reproductive and Respiratory Syndrome Virus
(PRRSV) antigens with improved immunogenicity and meth
ods for their use. The compositions and methods described
herein result in improved immunogenic responses of pigs to
PRRSV antigens, thus providing for improved protection of
pigs to PRRSV infection.

30

35

2. Related Art

PRRSV is an economically important pathogen that affects
pigs. Infection of sows and gilts with PRRSV can result in
reproductive failure. PRRSV also causes respiratory disease
in pigs of allages. It is possible to vaccinate the pigs to protect

40

them from infection with PRRSV. However, the current com

mercially available vaccines (most of which are live attenu
ated vaccines) are somewhat ineffective and therefore should
be improved. The complete immunologic mechanisms of
protection against PRRSV are not clear; however, it has been
clearly shown that PRRSV-neutralizing antibodies are central
to this protection. Unfortunately, the PRRSV itself (in its
wild-type form) or the current live vaccines derived from it
have poor ability to induce virus-specific neutralizing anti
bodies in a timely manner and at effective (i.e., protective)

Annu. Rev. Biochem. 73:1019-1049, 2004; Williams, D. B.
45

50

levels.

U.S. Pat. No. 6,500,662, “Infectious cDNA clone of North

American porcine reproductive and respiratory syndrome
(PRRS) virus and uses thereof (by Calvert et al., Dec. 31,
2002) describes the development of an infectious North

55

American PRRSV cDNA clone and its use as a vaccine.

However, U.S. Pat. No. 6,500,662 does not disclose PRRSV

vaccines that comprise hypoglycosylated PRRSV antigens.
In another study, sequences of the GP5 protein (or ORF5
protein) from various North American PRRSV strains were
compared to one another and to the representative European
PRRSV isolate known as the Lelystad strain, revealing that
the N-linked glycosylation sites at Asparagine 44 (N44) and
Asparagine 51 (N51) of the GP5 consensus sequence were
conserved in all of the PRRSV isolates examined (Pirzadeh et
al., Can. J. Vet Res., 1998, 62:170-177). However, the N-gly
cosylation site located at Asparagine 31 (N31) of the GP5

2
consensus sequence was absent in certain North American
PRRSV isolates and absent in the European PRRSV Lelystad
strain isolate. Recombinant GST-GP5 fusion proteins from
four (4) North American PRRSV strains and the Leylstad
strain were produced in E. coli as insoluble inclusion bodies,
renatured, and used as immunogens in rabbits. Such recom
binant proteins produced in E. coli retain but do not glycosy
late their native N-glycosylation sites.
Inoculation of pigs with a DNA vaccine comprising a
CMV promoterfusion to the GP5 gene of the IAF-Klop North
American PRRSV isolate has also been shown to provide
protection in immunized animals against PRRSV challenge
(Pirzadeh and Dea, 1998, J. General Virology, 79,989-999).
This particular GP5 gene isolate encodes a GP5 protein con
taining the N31, N44 and N51 Asparagine residues that are
presumably glycosylated when expressed in pigs immunized
with the DNA vaccine. Vaccination of pigs with E. coli pro
duced GST-GP5, which retain but do not glycosylate the
native N-glycosylation sites of the GP5 gene of the IAF-Klop
strain, did not protect the lungs of virus-challenged pigs.
European PRRSV infectious clones containing mutations
that result in expression of hypoglycosylated PRRSV pro
teins have also been described (Wissink et al., 2004, J. Gen.
Virol. 85:3715-23). This particular reference reports that
PRRSV containing mutations in the Asparagine Residue 53
(N53) of the PRRSV Lelystad strain GP(5) protein that pre
vent N-linked glycosylation of that site are infectious and can
produce infectious PRRSV Lelystad strain virus particles. In
contrast, PRRSV containing mutations in the N46 of the
PRRSV Lelystad strain GP(5) protein that prevent N-linked
glycosylation of that site are not infectious and do not produce
infectious PRRSV Lelystad strain virus particles. Wissink et
al. speculate that N-glycan sites in the European PRRSV
GP protein, and, by analogy, the N53 site of the GP5 pro
tein, could act at many different levels in the natural host,
including receptor interactions or immune shielding.
In viruses other than PRRSV, glycan residues have been
implicated in a variety of roles. The N-linked glycosylation,
in general, is important for correct folding, targeting, and
biological activity of proteins (Helenius, A. and M. Aebi.

60

65

and GlycoconjJ., 12:iii-iv, 1995; Zhang, et al., Glycobiology
14:1229-46, 2004). In many enveloped viruses, the envelope
proteins are modified by addition of Sugar moieties and the
N-linked glycosylation of envelope protein plays diverse
functions of viral glycoproteins such as receptor binding,
membrane fusion, penetration into cells, and virus budding
(Braakman, I. and E. van Anken, Traffic 1:533-9, 2000: Doms
et al. Virology 193:545-62, 1993). Recent studies have dem
onstrated the role of N-linked glycosylation of Hantaan virus
glycoprotein in protein folding and intracellular trafficking
(Shi, X. and R. M. Elliott, J. Virol. 78:5414-22, 2004) as well
as in biological activity and antigenicity of influenza virus
hemagglutinin (HA) protein (Abe.Y., et al., J. Virol. 78:9605
11, 2004). Furthermore, it has become evident that glycosy
lation of viral envelope proteins is a major mechanism for
viral immune evasion and persistence used by several differ
ent enveloped viruses to escape, block or minimize the virus
neutralizing antibody response. Examples of this effect have
been reported for SIV (Reitter, J. N. et al., Nat. Med. 4:679
84, 1998) and HIV-1 (Wei, X. et al., Nature 422:307-12,
2003), HBV (Lee, J. et al. Biochem. Biophys. Res. Commun.
303:427-32, 2003), influenza (Skehel, J.J. et al., Proc. Natl.

US 7,608,272 B2
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3
Acad. Sci. USA 81:1779-83, 1984) and the arterivirus LDV
(Chen, Z. et al. Virology 266:88-98, 2000).
SUMMARY OF THE INVENTION

It is in view of the above problems that the present inven
tion was developed. It is demonstrated that hypoglycosylated
variants of a PRRSV major surface protein GP5 increased the
level of PRRSV-neutralizing antibodies produced by immu
nized pigs relative to the levels of neutralizing antibodies
produced by pigs immunized with wild type (wt) or glycosy

10

lated GP5.

This invention first provides for a method of eliciting an
improved immune response in a pig to a Porcine Reproduc
tive and Respiratory Syndrome Virus (PRRSV) antigen, com
prising the administration of a composition comprising a
polynucleotide encoding a hypoglycosylated PRRSV GP5
polypeptide variant wherein at least one N-linked glycosyla
tion site corresponding to asparagine 34 or asparagine 51 in a
reference GP5 protein of SEQ ID NO:1 is inactivated. In
certain embodiments of the method, at least one N-linked
glycosylation site corresponding to asparagine 34 or aspar
agine 51 in SEQID NO:1 is inactivated. This polynucleotide
can comprise an infectious PRRSV RNA molecule or a DNA

molecule that encodes an infectious PRRSV RNA molecule.
The infectious PRRSV RNA molecule is a North American

15

25

PRRSV derivative or a European PRRSV derivative. Alter
natively, this polynucleotide can comprise a DNA molecule
wherein a promoter active in mammalian cells is operably
linked to said polynucleotide encoding a hypoglycosylated
GP5 protein. This promoter is a CMV promoter in certain

preferred embodiments of the invention. Alternatively, the
polynucleotide can be a viral vector. Representative viral
vectors that can be used include vaccinia virus vectors, a
herpes simplex viral vectors, adenovirus vectors, alphavirus

esis of a North American PRRSV isolate GP5 nucleotide

sequence or mutagenesis of a consensus North American
PRRSV GP5 nucleotide sequence. The North American
PRRSV isolate GP5 nucleotide sequence can be selected
from the group of nucleotides that encode the GP5 proteins of
SEQID NO:1, SEQID NO:2, SEQID NO:3, SEQID NO:4,
SEQID NO:5, SEQID NO:6, SEQID NO:7, SEQID NO:8,
SEQ ID NO:9, SEQ ID NO:10, SEQID NO:11, SEQ ID
NO:12, and SEQID NO:13. The consensus North American
PRRSV GP5 nucleotide sequence encodes a consensus GP5
protein that is at least 85% identical to SEQID NO:14. In
other embodiments of the invention, the polynucleotide
encoding a hypoglycosylated PRRSV GP5 polypeptide vari
antis obtained by direct synthesis, mutagenesis of a European
PRRSV isolate GP5 nucleotide sequence or mutagenesis of a
consensus European PRRSV GP5 nucleotide sequence. The
European PRRSV isolate GP5 nucleotide sequence encodes a
GP5 protein that is at least 85% identical to SEQID NO:15.
A variety of methods of inactivating specified N-linked
glycosylation sites can be used to effectively practice the
method of this invention. One preferred method of inactivat
ing an N-linked glycosylation site corresponding to aspar
agine 51 is to replace the asparagine codon with a codon

another amino acid can encode an alanine or a glutamine
residue. In other preferred embodiments, both of the N-linked
glycosylation sites corresponding to asparagine 34 and aspar
agine 51 in a reference GP5 protein can be inactivated by
replacing codons encoding the asparagine 34 and the aspar
agine 51 with codons encoding an amino acid other than
asparagine. Both codons encoding the asparagine 34 and the
asparagine 51 can be replaced with codons encoding eitheran
alanine or a glutamine residue to inactivate those glycosyla
tion sites. Alternatively, both codons can be replaced with
codons that encode analanine residue to inactivate both gly
cosylation sites. Alternatively, one of the N-linked glycosy
lation sites is inactivated by replacing one codon encoding
said asparagine 34 or said asparagine 51 with a codon encod
ing an amino acid other than asparagine while the other
N-linked glycosylation site is inactivated by other techniques.
In preferred embodiments, the method employs an infec

tious PRRSV RNA molecule that is a North American

35

vectors, and TGEV vectors.

A variety of types and sources of PRRSV sequences can be
used to obtain the polynucleotide encoding a hypoglycosy
lated PRRSV GP5 polypeptide variant wherein at least one
N-linked glycosylation site corresponding to asparagine 34 or
asparagine 51 in a reference GP5 protein of SEQID NO.1 is
inactivated. In certain embodiments of the invention, a poly
nucleotide encoding a hypoglycosylated PRRSV GP5
polypeptide variant is obtained by direct synthesis, mutagen

encoding an amino acid other than asparagine. This replace
ment codon can encode analanine or a glutamine residue. In
more preferred embodiments, both of said N-linked glycosy
lation sites corresponding to asparagine 34 and asparagine 51
in a reference GP5 protein of SEQIDNO:1 are inactivated. In
other embodiments, the N-linked glycosylation site corre
sponding to asparagine 34 is inactivated. This asparagine 34
N-linked glycosylation site can be inactivated by replacing a
codon encoding said asparagine 34 with a codon encoding an
amino acid other than asparagine. The codon encoding

40

45

50

55
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PRRSV derivative encoding a hypoglycosylated PRRSV
GP5 polypeptide variant protein wherein at least one
N-linked glycosylation site corresponding to asparagine 34 or
asparagine 51 in a reference GP5 protein of SEQID NO:1 is
inactivated. In more preferred embodiments, both of said
N-linked glycosylation sites corresponding to asparagine 34
and asparagine 51 in a reference GP5 protein of SEQID NO:1
are inactivated. Both of the N-linked glycosylation sites cor
responding to asparagine 34 and asparagine 51 in a reference
GP5 protein can be inactivated by replacing codons encoding
the asparagine 34 and the asparagine 51 with codons encod
ing an amino acid other than asparagine. Both codons encod
ing the asparagine 34 and the asparagine 51 can be replaced
with codons encoding either analanine or a glutamine residue
to inactivate those glycosylation sites. Alternatively, both
codons can be replaced with codons that encode an alanine
residue to inactivate that glycosylation site.
To practice this method, the polynucleotide containing
composition is administered by subcutaneous injection, intra
venous injection, intradermal injection, parenteral injection,
intramuscular injection, needle free injection, electropora
tion, oral delivery, intranasal delivery, oronasal delivery, or
any combination thereof. The administered composition can
further comprise a therapeutically acceptable carrier. This
therapeutically acceptable carrier is selected from the group
consisting of a protein, a buffer, a surfactant, and a polyeth
ylene glycol polymer, or any combination thereof.
The administered composition can further comprise an
adjuvant. This adjuvant can be aluminum hydroxide, Quil A.
an alumina gel suspension, mineral oils, glycerides, fatty
acids, fatty acid by-products, mycobacteria, and CpG oli
godeoxynucleotides, or any combination thereof. The admin
istered composition can also comprise a second adjuvant Such
as interleukin 1 (IL-1), IL-2, IL4, IL-5, IL6, IL-12, gamma
interferon (g-IFN), cell necrosis factor, MDP (muramyl
dipeptide), immuno stimulant complex (ISCOM), and lipo

65 SOCS.

The improved immune response of a pig to a PRRSV
antigen can comprise increased production of PRRSV neu

US 7,608,272 B2
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tralizing antibodies by said pig. Increased production of
PRRSV neutralizing antibodies is typically observed upon
immunization of the pig by the methods and compositions of
this invention. The improved immune response can be
obtained in a Sow, a gilt, a boar, or a piglet.
The invention also provides a method of eliciting an
improved immune response in a pig to a Porcine Reproduc
tive and Respiratory Syndrome Virus (PRRSV) antigen, com
prising the administration of a composition comprising a
hypoglycosylated PRRSV GP5 polypeptide variant wherein
at least one N-linked glycosylation site corresponding to
asparagine 34 or asparagine 51 in a reference GP5 protein of
SEQ ID NO:1 is inactivated to said pig. Hypoglycosylated
PRRSV GP5 polypeptide variant protein can be produced by
the same polynucleotides used in the previously described
methods in bacterial, yeast, or mammalian expression sys

10

15

temS.

The instant invention also provides for compositions com
prising a polynucleotide encoding a hypoglycosylated North
American PRRSV GP5 polypeptide variant wherein at least
one N-linked glycosylation site corresponding to asparagine
51 in a reference GP5 protein of SEQID NO:1 is inactivated,
and a therapeutically acceptable carrier. In certain embodi
ments, the compositions comprise polynucleotides where
both N-linked glycosylation sites corresponding to aspar
agine 34 and asparagine 51 in SEQID NO:1 are inactivated.
In preferred embodiments, this composition can comprise
either an infectious North American PRRSV RNA molecule
or a DNA molecule that encodes an infectious North Ameri

can PRRSV RNA molecule. In other embodiments, the poly
nucleotide comprises a DNA molecule wherein a promoter
active in mammalian cells is operably linked to said poly
nucleotide encoding said hypoglycosylated North American
PRRSV GP5 polypeptide variant. In certain preferred
embodiments, this promoter is a CMV promoter. In still other
embodiments, the polynucleotide in the composition com
prises a viral vector. Viral vectors that can be used in the
composition can be any one of a vaccinia virus vector, a
herpes simplex viral vector, an adenovirus vector, an alphavi
rus vector, and a TGEV vector.

In the polynucleotides of the composition, an N-linked
glycosylation site is inactivated by replacing a codon encod
ing said asparagine 51 with a codon encoding an amino acid
other than asparagine. The codon encoding an amino acid
other than asparagine encodes an alanine or a glutamine resi
due. In other embodiments of this composition, an additional
N-linked glycosylation site is inactivated by replacing a
codon encoding asparagine 34 with a codon encoding an
amino acid other than asparagine. This codon encoding
another amino acid can encode an alanine or a glutamine
residue. Preferred compositions comprising polynucleotides
encoding a hypoglycosylated North American PRRSV GP5
polypeptide variant protein wherein both of said N-linked
glycosylation sites corresponding to asparagine 34 and aspar
agine 51 in a North American reference GP5 protein of SEQ
ID NO:1 are inactivated are thus provided for by this appli
cation. Both of the said N-linked glycosylation sites can be
inactivated by replacing codons encoding said asparagine 34
and said asparagine 51 with codons encoding an amino acid
other than asparagine. These codons encoding an amino acid
other than asparagine can encode either an alanine or a
glutamine residue.
The therapeutically acceptable carrier used in the compo
sition can be a protein, a buffer, a Surfactant, and a polyeth
ylene glycol polymer, or any combination thereof. The com
position further comprises at least one adjuvant.
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This adjuvant can be aluminum hydroxide, Quil A, an
alumina gel Suspension, mineral oils, glycerides, fatty acids,
fatty acid by-products, mycobacteria, and CpG oligodeoxy
nucleotides, or any combination thereof. The composition
can further comprise a second adjuvant selected from the
group consisting of interleukin 1 (IL-1). IL-2, IL4, IL-5, IL6.
IL-12, gamma interferon (g-IFN), cell necrosis factor, MDP
(muramyl dipeptide), immuno stimulant complex (ISCOM),
and liposomes.
A composition comprising a hypoglycosylated North
American PRRSV GP5 polypeptide variant wherein at least
one N-linked glycosylation site corresponding to asparagine
51 in a reference GP5 protein of SEQID NO:1 is inactivated
and a therapeutically acceptable carrier is also provided by
this invention. In preferred embodiments, N-linked glycosy
lation sites corresponding to both asparagine 34 or asparagine
51 in a reference GP5 protein of SEQ ID NO:1 are inacti
vated. Hypoglycosylated PRRSV GP5 polypeptide variant
protein can be produced by the same polynucleotides used in
the previously described methods in bacterial, yeast, or mam
malian expression systems.
The instant invention also provides isolated polynucle
otides encoding a hypoglycosylated North American PRRSV
GP5 polypeptide variant wherein at least one N-linked gly
cosylation site corresponding to asparagine 51 in a reference
GP5 protein of SEQ ID NO:1 is inactivated. In certain
embodiments, polynucleotides where both N-linked glycosy
lation sites corresponding to asparagine 34 and asparagine 51
in SEQ ID NO:1 are inactivated are provided. In preferred
embodiments, this isolated polynucleotide can comprise
either an infectious North American PRRSV RNA molecule
or a DNA molecule that encodes an infectious North Ameri

can PRRSV RNA molecule. In other embodiments, the iso
35
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lated polynucleotide comprises a DNA molecule wherein a
promoteractive in mammalian cells is operably linked to said
polynucleotide encoding said hypoglycosylated North
American PRRSV GP5 polypeptide variant. In certain pre
ferred embodiments, this promoter is a CMV promoter. In
still other embodiments, the isolated polynucleotide com
prises a viral vector. Viral vectors that can be used in the
composition can be any one of a vaccinia virus vector, a
herpes simplex viral vector, an adenovirus vector, an alphavi
rus vector, and a TGEV vector.
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In the isolated polynucleotides an N-linked glycosylation
site is inactivated by replacing a codon encoding said aspar
agine 51 with a codon encoding an amino acid other than
asparagine. The codon encoding an amino acid other than
asparagine encodes analanine or a glutamine residue. In other
preferred embodiments, an additional N-linked glycosylation
site is inactivated by replacing a codon encoding asparagine
34 with a codon encoding an amino acid other than aspar
agine. This codon encoding anotheramino acid can encode an
alanine or a glutamine residue. Preferred polynucleotides
encoding a hypoglycosylated North American PRRSV GP5
polypeptide variant protein wherein both of said N-linked
glycosylation sites corresponding to asparagine 34 and aspar
agine 51 in a North American reference GP5 protein of SEQ
ID NO:1 are inactivated are thus provided. Both of the said
N-linked glycosylation sites can be inactivated by replacing
codons encoding said asparagine 34 and said asparagine 51
with codons encoding an amino acid other than asparagine.
These codons encoding an amino acid other than asparagine
can encode either an alanine or a glutamine residue.
The invention also provides for an isolated polypeptide that
is a hypoglycosylated North American PRRSV GP5 polypep
tide variant wherein at least one N-linked glycosylation site
corresponding to asparagine 51 in a reference GP5 protein of
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treated with (+) or without (-) Endo H and analyzed by
electrophoresis. GP5 with and without Endo H digestion in
lanes 1 and 2 are shown by white brackets. B. Cells infected

7
SEQID NO:1 is inactivated. The isolated hypoglycosylated
PRRSV GP5 polypeptide variant protein can be produced by
the same polynucleotides used in the previously described
methods in bacterial, yeast, or mammalian expression sys
tems and purified by chromatography or other techniques.
Further features and advantages of the present invention, as
well as the structure and operation of various embodiments of
the present invention, are described in detail below with ref
erence to the accompanying drawings.

with various mutant viruses were radiolabeled, GP5 was

10

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in
and form a part of the specification, illustrate the embodi
ments of the present invention and together with the descrip
tion, serve to explain the principles of the invention. In the
drawings:
FIG. 1 illustrates the transient Expression of PRRSV GP5
and M protein. A. Schematic of the bicistronic construct
showing the GP5 and M coding regions flanking the IRES
(IE) from encephalomyocarditis virus. The coding regions
are under the control of T7 RNA polymerase promoter (black
rectangle) present immediately upstream of the GP5 coding
region. The bent arrow shows the position and direction of
transcription by T7 RNA polymerase from the vector. B.
Expression of GP5 and M proteins in cells transfected with
the bicistronic vector. Mock-transfected (lane 1) or plasmid
transfected cells (lanes 2-7) were radiolabeled as described in
Materials and Methods, immunoprecipitated with anti-Gp5
antibody (lanes 1-5) or anti-Mantibody (lanes 6-7). Immu
noprecipitated proteins were left untreated (-) (lanes 1, 2, 6.
and 7) or treated (+) with Endo H(lane 3), PNGase F (lane 4)
and analyzed by electrophoresis. Lane 5 contains immuno
precipitated proteins from transfected cells treated (+) with
tunicamycin. Mobility of proteins with relative molecular
mass (Mr) in kilodaltons are shown.
FIG. 2 illustrates the glycosylation analysis of WTGP5
and its mutants using a bicistronic plasmid. A. Schematic of
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DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENTS
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Definitions

35

the bicistronic vector and the PRRSV GP5 with the three

putative glycosylation sites atamino acid positions 34, 44 and
51 shown. B. Various mutants used in the present study. C.
Expression of wt and mutant GP5 and their sensitivity to
Endo H. The experiment was performed as described in the
legend to FIG. 1, proteins were immunoprecipitated with
anti-GP5 antibody, digested with Endo H (+) or left undi
gested (-) and analyzed by electrophoresis. Mutant GP5 pro
teins are shown by arrowheads. Mobility of proteins with
relative molecular mass (Mr) in kilodaltons are shown on
right.

40

FIG. 3 illustrates the characterization of mutant viruses

50

encoding mutant GP5. A. Single step growth kinetics of wt
(FL-12) and various mutant PRRSVs in MARC-145 cells.
Cells in six-well plated were infected with PRRSVatan MOI
of 3, culture supernatants were collected at indicated times
after infection and virus titers were determined. Average titers
with standard deviation (error bars) from three independent
experiments are shown. B. Plaque morphology of mutant
viruses. Open arrows and arrowheads show plaques that are
less clear. C. Trans-complementation to recover mutant
PRRSVs. Quantitative analysis of mutant virus recovery from
cells expressing wt GP5 protein. Average yield of viruses
from three independent experiments with standard deviation
(represented by error bars) is shown.
FIG. 4 illustrates an examination of GP5 incorporated into
mutant virions and synthesized in mutant virus-infected cells.
A. Radiolabeled virions from culture supernatants of infected
cells were pelleted, GP5 protein was immunoprecipitated,

immunoprecipitated, treated with (+) or without (-) Endo H
and analyzed by electrophoresis. GP5 with and without Endo
H digestion in lanes 2 and 3 are shown by white brackets.
Mobility of proteins with relative molecular mass (Mr) in
kilodaltons are shown on right side of each panel.
FIG.5 illustrates an alignment of North American PRRSV
GP5 n-terminal amino acid sequences with the North Ameri
can PRRSV GP5 reference n-terminal sequence (SEQ ID
NO:1; strain NVSL 97-7895). The first 60 N-terminal amino
acids of an alignment of the 200 amino acid proteins are
shown. The asparagine 34“NSS and asparagine 51 “NGT
N-linked glycosylation sites in the proteins are shown in bold.
Other N-linked glycosylation sites located between residues
29 and 35 of the reference GP5 protein are underlined.
FIG. 6 illustrates an alignment of European PRRSV GP5
N-terminal amino acid sequence with the North American
PRRSV GP5 reference n-terminal sequence (SEQID NO:1;
strain NVSL 97-7895). An alignment of the entire GP5 pro
tein of approximately 200 amino acid proteins is shown
where the asparagine 51 “NGT N-linked glycosylation site
in the proteins is shown in bold (i.e., asparagine 53 in SEQID
NO:15).

Acceptable carrier, as used herein, refers to a carrier that
is not deleterious to the other ingredients of the composition
and is not deleterious to material to which it is to be applied.
“Therapeutically acceptable carrier refers to a carrier that is
not deleterious to the other ingredients of the composition and
is not deleterious to the human or other animal recipient
thereof. In the context of the other ingredients of the compo
sition, “not deleterious' means that the carrier will not react

with or degrade the other ingredients or otherwise interfere
with their efficacy. Interference with the efficacy of an ingre
dient does not encompass mere dilution of the ingredient. In
the context of the animal, “not deleterious' means that the
45
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carrier is not injurious or lethal to the plant or animal.
'Adjuvant, as used herein, refers to any material used in
conjunction with an antigen that enhances the ability of that
antigen to induce an immune response.
Administration’, as used herein, refers to any means of
providing a polynucleotide, a polypeptide or composition
thereof to a subject. Non-limiting examples of administration
means include Subcutaneous injection, intravenous injection,
intradermal injection, parenteral injection, intramuscular
injection, needle free injection, electroporation, oral delivery,
intranasal delivery, oronasal delivery, or any combination
thereof.
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"Antigen', as used herein, refers to any entity that induces
an immune response in a host.
“Consensus sequence', as used herein, refers to an amino
acid, DNA or RNA sequence created by aligning two or more
homologous sequences and deriving a new sequence that
represents the common amino acid, DNA or RNA sequence.
“Hypoglycosylated PRRSV GP5 polypeptide variant', as
used herein, refers to PRRSV GP5 proteins wherein the origi
nal or non-variantamino acid sequence that comprises one or
more N-linked glycosylation sites has been changed so as to
reduce the number of N-linked glycosylation sites in the
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resultant GP5 variant protein. Under this definition, expres
sion of an original or non-variant GP5 protein in E. coli to
produce a GP5 protein with the original GP5 sequence con
taining the same number of glycosylation sites would not
result in production of a hypoglycosylated PRRSV GP5
polypeptide variant.
“Immune response', as used herein, refers to the produc
tion of antibodies and/or cells (such as T lymphocytes) that
bind, degrade or otherwise inhibit, a particular antigen.
Related phrases such as “an improved immune response'
refer to the use of the methods and compositions that result in
any measurable improvement in the response of an immu
nized host to an antigen. For example, measurable improve
ments in an immune response include, but are not limited to,
increased production of neutralizing antibodies (i.e.,
increased antibody titers) relative to the levels of production

Introduction

10

15

clone to recover infectious PRRSV. Our results demonstrate

observed in control animals that have been immunized with

antigens that lack the structural modifications that provide for
an improved immune response.
"Infectious RNA molecule” refers to an RNA molecule

that encodes all necessary elements for production of a func
tional virion when introduced into a permissive host cell.
"Infectious clone', as used herein, refers to a DNA mol

25

ecule that encodes an infectious RNA molecule.

“North American PRRSV, as used herein, refers to any
PRRSV comprising polynucleotide sequences associated
with a North American PRRSV isolates, such as, but not

limited to, the NVSL 97-7895 strain (Truong etal, Virology,
325:308-319 and references contained therein) or IAF-Klop,

30

MLV, ATCC VR-2332, ATCC VR-2385, IAF-BAJ, IAF
DESR, IAF-CM, IAF 93-653, IAF 93-2616, IAF 94-3 182,
IAF 94-287 Strains described in Pirzadeh et al. Can. J. Vet

Res, 62: 170-177 and references contained therein). For this
invention, PRRSV comprising polynucleotide sequences

35

associated with a North American PRRSV isolates are

PRRSV containing polynucleotide sequences wherein the
GP5 encoding region encodes a polypeptide that has at least
85% protein sequence identity to SEQID NO:1.
“European PRRSV, as used herein, refers to any PRRSV
comprising polynucleotide sequences associated with a

40

North American PRRSV isolates, such as, but not limited to,

the Lelystad strain (Wissink et al., J. Gen. Virol. 85:3715,
2004 and references contained therein). For this invention,
PRRSV comprising polynucleotide sequences associated
with a European PRRSV isolates are PRRSV containing
polynucleotide sequences wherein the GP5 encoding region
encodes a polypeptide that has at least 85% protein sequence
identity to SEQID NO:15.
“Percent identity”, as used herein, refers to the number of
elements (i.e., amino acids or nucleotides) in a sequence that
are identical within a defined length of two optimally aligned
DNA, RNA or protein segments. To calculate the “percent
identity”, the number of identical elements is divided by the
total number of elements in the defined length of the aligned
segments and multiplied by 100. When percentage of identity
is used in reference to proteins it is understood that certain
amino acid residues may not be identical but are nonetheless
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increased to account for conservative substitutions.

that mutations involving N44 residue did not result in infec
tious progeny production, indicating that N44 is the most
critical amino acid residue for viral infectivity. Viruses car
rying mutations at N34, N51, and N34/51 grew to lower titers
than the wt PRRSV and exhibited reduced cytopathic effect in
MARC 145 cells. In serum neutralization assays, the mutant
viruses exhibited enhanced sensitivity to neutralization by wt
PRRSV-specific antibodies. Furthermore, inoculation of pigs
with the mutant viruses induced significantly higher levels of
neutralizing antibodies against the mutant as well as the wt
PRRSV, thus suggesting that the loss of glycan residues in the
ectodomain of GP5 enhances both the sensitivity of these
viruses to in vitro neutralization as well as the immunogenic
ity of the nearby neutralization epitope. These results should
have great significance for development of PRRSV vaccines
of enhanced protective efficacy.
Neutralizing antibodies are known to be a major correlate
of protection against PRRSV. We have found that elimination
of glycosylation sites in PRRSV GP5 protein results in sig
nificant enhancement of: (1) the ability of the modified
PRRSV strain to be neutralized by a PRRSV convalescent
antiserum and (2) the ability of this modified PRRSV strain to
produce unprecedented levels of PRRSV-neutralizing anti
bodies when used to inoculate pigs. The application of this
concept to any live (wt or attenuated) virus used for immu
nizing against PRRSV infection would have significant
impact in its usage to confer effective protection against
PRRSV infection.

At the current time, there exists three main approaches to
immunize against PRRSV infections: (1) live attenuated vac
cines, (2) inactivated vaccines (which are based on wt
PRRSV grown in vitro and chemically inactivated), and (3)
use of purposeful infection with virulent wt PRRSV in a
systematic manner to all animals of the herd. There is a lot of
discussion and controversy about which of these 3 ways is the
most effective. Our invention would be beneficial, regardless
of the approach used for immunization. The genetic alteration
of a live PRRSV to modify the glycosylation level of its
proteins can be done in either the attenuated PRRSV vaccine
strain, or the wt PRRSV strain used to produce an inactivated
vaccine, or the wt PRRSV strain used for directinoculation of

60

conservative amino acid substitutions that reflect substitu

tions of amino acid residues with similar chemical properties
(e.g., acidic or basic, hydrophobic, hydrophilic, hydrogen
bond donor or acceptor residues). Such substitutions may not
change the functional properties of the molecule. Conse
quently, the percent identity of protein sequences can be

The porcine reproductive and respiratory syndrome virus
(PRRSV) glycoprotein 5 (GP5) is the most abundant enve
lope glycoprotein and a major inducer of neutralizing anti
bodies in vivo. Three putative N-linked glycosylation sites
(N34, N44, and N51) are located on the GP5 ectodomain,
where a major neutralization epitope also exists. To determine
which of these putative glycosylation sites are used in
PRRSV life cycle and the role of the glycan moieties in
induction of neutralizing antibodies, we generated a panel of
GP5 mutants containing single and multiple amino acid Sub
stitutions at these sites. Transient expression of the wild-type
(wt) as well as the mutant proteins and Subsequent biochemi
cal studies revealed that the mature GP5 contains high-man
nose type Sugar moieties at all three sites. These mutations
were subsequently incorporated into a full-length cDNA

65

the herd by mass infection.
The porcine reproductive and respiratory syndrome virus
(PRRSV) belongs to the family Arteriviridae within the order
Nidovirales that also includes equine arteritis virus (EAV),
lactate dehydrogenase-elevating virus (LDV), and simian
hemorrhagic fever virus (SHFV). The viral genome is a lin
ear, positive stranded RNA molecule of approximately 15.0
kb in length and possesses a cap structure at the 5'-end and a
poly(A)tail at the 3'-end. Eight open reading frames (ORF)
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are encoded in the viral genome. The first two open reading
frames (ORF1a and ORF1ab) encode viral non-structural
(NS) polyproteins that are involved in polyprotein processing
and genome transcription and replication. The viral structural
proteins, encoded in ORF2-7, are expressed from six subge
nomic capped and polyadenylated mRNAS that are synthe

12
nose type glycans and glycosylation of GP5 protein at residue
44 is critical for recovery of infectious PRRSV. Very impor
tantly, our data from neutralization and antibody response
studies indicate that natural infection with PRRSV may
involve an immune evasion based on glycan shielding mecha
nisms as was previously described for other viruses, thus
helping to explain the rather ineffective protective humoral
immune response that is observed in PRRSV-infected ani

sized as 3'-coterminal nested set of mRNAs with a common

leader sequence at the 5' end. The major viral envelope pro
tein is the glycoprotein 5 (GP5), which is encoded in the
ORF5 of the viral genome. GP5 is a glycosylated transmem
brane protein of approximately 25 kDa in size. It has a puta
tive N-terminal signal peptide and possesses three potential
N-linked glycosylation sites which are located in a small
ectodomain comprising the first 40 residues of the mature
protein. In EAV and LDV, the major envelope glycoprotein
forms a disulfide-linked heterodimer with the ORF6 gene
product, the viral matrix (M) protein. Similar interaction
between PRRSV GP5 and M protein has been observed but
the mode of interaction has not been defined yet. It has been
postulated that formation of heterodimers of GP5 and M
proteins may play a critical role in assembly of infectious
PRRSV. In addition to its role in virus assembly, GP5 appears
to be involved in entry of the virus into susceptible host cells.
GP5 is presumed to interact with the host cell receptor, sia
loadhesin for entry into porcine alveolar macrophages
(PAMs), the in vivo target cells for PRRSV. The role of GP5
in receptor recognition is Supported by the presence of a
major neutralization epitope in the N-terminal ectodomain,
thus implying a central role for the GP5 ectodomain in the
infection process.
The N-linked glycans of the GP5 ectodomain may be criti
cal for proper functioning of the protein. The N-linked gly
cosylation, in general, is important for correct folding, target
ing, and biological activity of proteins. In many enveloped
viruses, the envelope proteins are modified by addition of
Sugar moieties and the N-linked glycosylation of envelope
protein plays diverse functions of viral glycoproteins such as
receptor binding, membrane fusion, penetration into cells,
and virus budding. Recent studies have demonstrated the role
of N-linked glycosylation of Hantaan virus glycoprotein in
protein folding and intracellular trafficking as well as in bio
logical activity and antigenicity of influenza virus hemagglu
tinin (HA) protein. Furthermore, it has become evident that
glycosylation of viral envelope proteins is a major mecha
nism for viral immune evasion and persistence used by sev
eral different enveloped viruses to escape, block or minimize
the virus-neutralizing antibody response. Examples of this
effect have been reported for SIV and HIV-1, HBV, influenza
and more importantly, in the case of PRRSV, the arterivirus
LDV.

Recently the development of reverse genetic systems for
PRRSV has been reported from several laboratories including
ours. Evidently, mutational studies with infectious clones
have led to a better understanding of the mechanisms of
transcription and replication of the viral genome of arterivi
ruses. Thus, in order to examine the importance of N-linked
glycosylation in the biological activity of GP5 of PRRSV in
generating infectious virus or eliciting neutralizing antibod

mals.
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amino acid insertions or amino acid deletions are also con
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ies in vivo, we have constructed a series of mutant GP5

proteins in which each of the potential N-linked glycosylation
sites has been mutated either individually or in various com
binations. The resulting mutant proteins were examined for
their glycosylation pattern, role in infectious virus recovery
and in cross neutralization by antibodies raised, through
experimental inoculations, against the wt PRRSV or against
the mutant viruses. Our data show that all three putative
glycosylation sites are used for glycosylation with high-man

N-Linked Glycosylation Sites and Methods of Inactivation
N-linked glycosylation in glycoproteins typically occurs at
Asn-Xaa-Ser/Thr (NXS/T) sequences, where Xaa (X) is any
amino acid residue except Pro. A variety of mutations can be
introduced at N-linked glycosylation sites to provide for their
inactivation. A preferred method of inactivation comprises
Substitution of the asparagine residue with a residue encoding
any amino acid other than asparagine. In more preferred
embodiments of this invention, the asparagine residue is Sub
stituted with an alanine or a glutamine residue.
Other methods of inactivating N-linked glycosylation
sites, and in particular the N-linked glycosylation sites cor
responding to asparagines 34 and/or 51 of the GP5 reference
protein of SEQID NO:1, are also contemplated herein. Sub
stitutions of certain amino acids such as proline, tryptophan,
aspartate, glutamate or Leucine at the Xaa position can also
be used to inactivate N-linked glycosylation sites (Kasturi et
al., Biochem J.323 (2):415-9, 1997). Alternatively, substitu
tions of the final hydroxy amino acid position of the N-linked
glycosylation site (i.e., the serine or threonine residue of the
NXS/T sequence) with any non-hydroxy amino acid (i.e., any
amino acid other than serine or threonine) can also be used to
inactivate the N-linked glycosylation site. Examples of non
hydroxy amino acids that have been used to inactivate
N-linked glycosylation sites include cysteine (Kasturietal., J.
Biol. Chemistry 270(24), 14756-14761, 1995).
In addition to amino acid Substitutions, other types of
mutations that inactivate N-linked glycosylation sites such as
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templated by this invention. Those skilled in the art will
appreciate that an N-linked glycosylation site can be readily
inactivated by deletions that remove key amino acids in the
NXS/T sequence (i.e., the asparagine residues) will result in
the inactivation of that glycosylation site. Deletions of the X
residue or serine/threonine residue can similarly inactivate
certain N-linked glycosylation sites where the S or T residue
is not followed by another S or T residue in the naturally
occurring sequence. When X is a non-hydroxy amino acid
(i.e., is not serine or threonine), insertions of any amino acid
residue at the carboxy terminal end of the N residue can
inactivate the N-linked glycosylation site. Insertions of any
non-hydroxy amino acids at the carboxy terminal end of theX
residue can also inactivate the N-linked glycosylation site.
In summary, it is understood that the key feature of the
mutation used to practice the invention is that it inactivates
N-linked glycosylation at the asparagine 34 and/or aspar
agine 51 sites in a GP5 protein. While not being limited by
theory, it is believed that the key feature of these mutations are
that they prevent glycosylation in a certain region of the
protein (i.e., residues corresponding to the asparagine 34
and/or asparagine 51 sites in a GP5 reference protein of SEQ
ID NO:1). By preventing glycosylation at these sites, Sugar
residues that ordinarily shield key epitopes of the wild type
virus are removed, thus permitting elicitation of an improved
immune response. Consequently, it is anticipated that a num
ber of different types of mutations (i.e., amino acid substitu
tion, insertion or deletion) can be used to inactivate the iden
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tified N-linked glycosylation sites and obtain an antigen that
will elicit the improved immune response.
Description of PRRSV Polynucleotides and Polypeptides of

TABLE 1-continued

Description of Sequences

the Invention

The methods of this invention can be practiced with a
variety of different polynucleotides that can be derived from
a variety of different sources. The common feature of all of
the polynucleotides is that they encode a hypoglycosylated
PRRSV GP5 polypeptide variant where N-linked glycosyla
tion sites corresponding to either asparagine 34, asparagine
51, or both asparagine 34 and asparagine 54 in a reference
GP5 protein of SEQID NO:1 are inactivated. To identify the
N-linked glycosylation sites corresponding to asparagine 34
and asparagine 54 in the reference GP5 protein of SEQ ID
NO:1, the non-variant and normally glycosylated PRRSV
GP5 polypeptide sequence can be aligned with the reference
GP5 protein of SEQID NO:1. Examples of such an alignment
are displayed in FIGS. 5 and 6. The particular sequences used
in this alignment are described in Table 1.

GenBank Accession

Sequence ID NO:
SEQ ID NO: 1

GPS Protein

AAS59265.1

North American PRRSV strain

(Truong, H. M., et

NVSL 97-7895

al. Virology 325

(2), 308-319,
2004)
GPS Protein

15

SEQ ID NO: 2

AAC41209.

SEQ ID NO:3

AAC41212.

SEQ ID NO:4

AAC41215.

SEQ ID NO:5:

AAC41218.

SEQ ID NO: 6

AAC41221.

SEQ ID NO: 7

AAC41224.

SEQ ID NO: 8

GPS Protein

AAC28399.1 (with

SEQ ID NO: 9:

North American PRRSV strain

Ser 106 as per

North American PRRSV strain

1. IAF-Klop
GPS Protein

GPS Protein
North American PRRSV strain
IAF-BA

GPS Protein

35

North American PRRSV strain
IAF-DESR

GPS Protein
North American PRRSV strain
IAF 93-653

GPS Protein

40

North American PRRSV strain
IAF 93-2616

GPS Protein
North American PRRSV strain
94-31.82

GPS Protein

45

North American PRRSV strain
94-287

IAF-CM

50

Pirzadeh, B., et
al. Can. J. Vet.

Res.62 (3), 170-177
(1998)
GPS Protein

AAC41227.

SEQ ID NO: 10

North American PRRSV strain
ONTTS

GPS Protein

55

AAD12129.

SEQ ID NO: 11

AAA67155.

SEQ ID NO: 12:

North American PRRSV strain
VR-2332

GPS Protein
North American PRRSV strain
VR-238S

GPS Protein

60

AAD27656.

SEQ ID NO: 13

SEQ ID NO: 14

North American PRRSV strain
MLV

GPS Protein

Pirzadeh, B., et

North American PRRSV strain

all. Can. J. Vet.

Consensus

Res.62 (3), 170-177

(1998)

AAA47105.1

SEQ ID NO: 15

AAS59265.

SEQ ID NO: 16

North American PRRSV strain

(Truong, H. M., et

NVSL 97-7895

al. Virology 325

PRRSV Infectious clone DNA

AY150564.

North American PRRSV strain

(Nielsen, H. S., et

VR-2332

al., J. Virol. 77

SEQ ID NO: 17

(6), 3702-3711,
2003)

30

AAC412O6.

GPS Protein

(2), 308-319,
2004)

25

(Reference)

Sequence ID NO:

LV
10 PRRSV Infectious clone DNA.

Description of Sequences
GenBank Accession

(Reference)

European PRRSV strain

TABLE 1.

Description

Description
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To identify N-linked glycosylation sites corresponding to
asparagine 34 or asparagine 51 in a reference GP5 protein of
SEQID NO: 1 that can be inactivated and used in the methods
of this invention, the GP5 proteins of either a desired North
American PRRSV isolate (FIG. 5) or a European PRRSV
isolate (FIG. 6) are aligned with reference GP5 protein of
SEQID NO: 1 (North American strain NVSL 97-7895). By
using the GP5 protein of SEQID NO:1 as a reference protein,
one skilled in the art can readily identify the N-linked glyco
sylation sites in any GP5 protein and then construct the
hypoglygosylated GP5 protein variants of this invention. It is
thus apparent that the term “corresponding to (asparagine 34
and/or asparagine 51) in a reference GP5 protein of SEQID
NO:1 serves as a descriptor of the N-linked glycosylation
site in any GP5 protein.
The hypoglycosylated GP5 protein can be obtained from a
North American PRRSV isolate including, but not limited to,
SEQID NO:1-13, a North American PRRSV isolate that is at
least 85% identical at an amino sequence level to a North
American PRRSV consensus sequence such as SEQ ID
NO:14, or from a North American PRRSV consensus

sequence. The hypoglycosylated GP5 protein can also be
obtained from European PRRSV isolates including, but not
limited to, SEQID NO:15, a European PRRSV isolate that is
at least 85% identical at an amino sequence level to a Euro
pean PRRSV consensus sequence such as SEQID NO:15, or
from a European PRRSV consensus sequence. To obtain the
hypoglycosylated GP5 variant encoding polynucleotides,
polynucleotides from any of the sources listed above can be
mutagenized by standard site-directed mutagenesis tech
niques such that they will encode a hypoglycosylated GP5
variant polypeptide. Alternatively, an entirely synthetic DNA
sequence can be constructed that encodes the desired
hypoglycosylated GP5 variant polypeptide. This is typically
accomplished by using a sequence analysis program Such as
“back translate' which converts a polypeptide sequence into
a corresponding polynucleotide sequence (GCG Wisconsin
PackageTM, Accelrys, Inc, San Diego, Calif.). If desired, a
suitable “codon bias’ can be incorporated into the “back
translate” program to provide for the design of a synthetic
gene that incorporates codons appropriate for use in the
desired expression host (i.e., mammalian or yeast).
The N-linked glycosylation site corresponding to aspar
agine 51 of the reference GP5 protein of SEQ ID NO:1 is
present in all of the representative North American PRRSV
isolates shown in FIG. 5 and in the representative European
PRRSV Lelystad strain (FIG. 6). In these exemplary and
non-limiting North American and European PRRSV strains,

US 7,608,272 B2
15
the N-linked glycosylation site at this position comprises the
sequence “NGT. However, it is also anticipated that other
PRRSV variants may comprise other structurally inter
changeable N-linked glycosylation sites at this position (i.e.,
NXS or T) that could also be inactivated via the methods
taught herein. This N-linked glycosylation site can be inacti
vated by Substituting codons encoding otheramino acid resi
dues such as glutamine or alanine for asparagine 51 in the
corresponding polynucleotide sequence. In these instances,
the corresponding amino acid sequence in the hypoglycosy
lated North American PRRSV GP5 protein variant would
comprise the sequences such as “QGT', 'AGT', or “XGT.
where X is any amino acid other than asparagine. These or
other hypoglycosylated variants of the North American
PRRSV GP5 protein isolates where the N-linked glycosyla
tion site corresponding to asparagine 51 is inactivated can
also be combined with other hypoglycosylated GP5 variants
where other N-linked glycosylation sites are inactivated.
Other methods of inactivating N-linked glycosylation sites

10

15

includeamino acid substitutions of the “X” or "S/T residues

of the NXS/T sequence, amino acid deletions or amino acid
insertions and are described above.

The N-linked glycosylation site corresponding exactly to
asparagine 34 of the reference GP5 protein of SEQID NO:1
is present in only certain representative North American
PRRSV isolates shown here (FIG. 5). More specifically, the
GP5 proteins of North representative American PRRSV iso
lates IAF-BAJ (SEQID NO:3), 94-3182 (SEQID NO:7), and
94-287 (SEQ ID NO:8) contain the N-linked glycosylation
site corresponding exactly to asparagine 34 of the reference
GP5 protein of SEQ ID NO:1 and comprises the N-linked
glycosylation site “NSS”. It is of course anticipated that other
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PRRSV GP5 isolates not shown here will also contain

N-linked glycosylation sites corresponding to asparagine 34
of the reference GP5 protein of SEQ ID NO:1 and that
hypoglycosylated variants of these other GP5 proteins can
also be obtained using the methods described herein. This
N-linked glycosylation site of SEQID NO:3, 7, and 8 or other
PRRSV isolates containing the asparagine 34 N-linked gly
cosylation site can be inactivated by Substituting codons
encoding other amino acid residues such as glutamine or
alanine for asparagine 34 in the corresponding polynucle
otide sequence. In these instances where the N-linked glyco
sylation site at asparagine 34 is “NSS, the corresponding
amino acid sequence in the hypoglycosylated North Ameri
can PRRSV GP5 protein variant would comprise the
sequences such as “QSS”, “ASS, or “XSS', where X is any
amino acid other than asparagine. Alternatively, the serine
residue of the “NSS' sequence can be substituted with a
non-hydroxy amino acid (i.e., non-serine of non-threonine).
In these instances, the corresponding amino acid sequence in
the hypoglycosylated North American PRRSV GP5 protein
variant would comprise the sequence “NSX', where X is any
amino acid other than asparagine. An insertion of a non
hydroxy amino acid between the two serine residues of the
“NSS' sequence (i.e., between serines 35 and 36) can also be
used to inactivate this particular glycosylation site.

35
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vated.
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The hypoglycosylated GP5 variant proteins can be
encoded by PRRS viruses that can be used to prepare live,
killed, or attenuated vaccines for protecting pigs from
PRRSV infections. In preferred embodiments of the inven
tion, the hypoglycosylated GP5 variant proteins of this inven
tion are engineered into infectious PRRSV clones that are
capable of producing infectious PRRSV RNA. Descriptions
of infectious North American PRRSV clones that could be

engineered to encode hypoglycosylated GP5 variant proteins
are found in U.S. Pat. No. 6,500,662, Nielsen et al., J. Virol.
55

77:3702-11, 2003, and Truong et al., Virology 325:308-19,
2004. North American PRRSV infectious clone sequences
that can be mutagenized to obtain PRRSV viruses for use in
vaccines include but are not limited to the North American

In other North American PRRSV isolates that lack the

N-linked glycosylation site corresponding exactly to aspar
agine 34 of the reference GP5 protein of SEQID NO:1, other
N-linked glycosylation sites located at residue 30 (FIG. 5
“NAS” in SEQID NO:2, 3, 4, 6, 7, 8, 9, 11, 13), and residue
33 (FIG. 5 “NNS” in SEQID NO:3, 8: “NSS” in SEQ ID
NO:6, 10, “NDS” in SEQID NO:11, 13) can also be inacti
vated. In other words, N-linked glycosylation sites in other
North American isolates located at amino acid positions cor
responding to residues 30 and 33 of the reference GP5 protein

16
of SEQ ID NO:1 can also be inactivated and used in the
methods of this invention. Without being limited by theory,
the particular region of the PRRSV GP5 protein located
between residues 29 and 35 of the GP5 reference protein of
SEQID NO:1 appears to be a hypervariable region (FIG. 5)
that can tolerate a variety of distinct amino sequences (FIG.5;
also see Pirzadeh et al., Can. J. Vet Res., 1998, 62: 170-177).
Although certain naturally occurring PRRSV isolates contain
no N-linked glycosylation sites in this region (i.e., North
American isolates of SEQID NO:5, 12: European isolate of
SEQ ID NO:15), other isolates can contain between 1 to 3
glycosylation sites in this region. Consequently, inactivation
of any one of the glycosylation sites of a given GP5 protein in
the region located between residues 29 and 35 of the GP5
reference protein of SEQID NO:1 is contemplated herein as
a composition or method for eliciting an improved immune
response to the PRRSV GP5 protein. Furthermore, inactiva
tion of more than one or all of the glycosylation sites a given
GP5 protein in the region located between residues 29 and 35
of the GP5 reference protein of SEQID NO:1 is also contem
plated herein as a composition or method for eliciting an
improved immune response to the PRRSV GP5 protein.
Alignment of the North American and the European
PRRSV sequence shows that the N-linked glycosylation site
corresponding to asparagine 51 of the reference GP5 protein
of SEQID NO:1 is also present in a representative European
PRRSV isolate. In this particular instance, the N-linked gly
cosylation site comprises the sequence “NGT and the aspar
agine 51 of the SEQID NO:1 reference sequence corresponds
to asparagine 53 of SEQID NO:15. This N-linked glycosy
lation site can be inactivated by Substituting codons encoding
other amino acid residues such as glutamine or alanine for
asparagine 53 in the corresponding European PRSSV poly
nucleotide sequence. In these instances, the corresponding
amino acid sequence in the hypoglycosylated European
PRRSV GP5 protein variant would comprise the sequences
such as “QGT”, “AGT', or “XGT, where X is any amino
acid other than asparagine. These or other hypoglycosylated
variants of the European PRRSV isolates where N-linked
glycosylation site corresponding to asparagine 51 is inacti
vated can also be combined with other hypoglycosylated GP5
variants where other N-linked glycosylation sites are inacti
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strains NVSL 97-7895 (SEQID NO:16) and strain VR-2332
(SEQ ID NO:17). Descriptions of infectious European
PRRSV clones that could be engineered to encode hypogly
cosylated GP5 variant proteins are found in U.S. Pat. No.
6.268,199. In embodiments where the vaccine comprises a
live or attenuated PRRSV, the N-linked glycosylation site
corresponding to N44 in the reference GP5 protein of SEQID
NO:1 (i.e., the “NLT sequence in FIGS. 5 and 6) is not
inactivated as glycosylation of this site is required for infec
tivity of the PRRSV. In the case of the European PRRSV
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isolates, the N-linked glycosylation site corresponding to
N44 in the reference GP5 protein of SEQID NO:1 is the NLT
sequence that begins at asparagine 46 of the representative
European PRRSV strain Lelystad (SEQ ID NO:15: FIG. 6).
The N46N-linked glycosylation site of the European PRRSV
strains is also required for infectivity and is not inactivated in

18
Needle free injection is typically effected with a device such
as an Agro-JetR) injector (Medical International Technolo
gies, Montreal, Canada).
5

EXAMPLES

embodiments of the invention where a live or attenuated
PRRSV vaccine is used.

Alternatively, the hypoglycosylated GP5 variant proteins
can be introduced into pigs with DNA vaccines. Such DNA
vaccines typically comprise a DNA molecule wherein a pro
moter active in mammalian cells is operably linked to said
polynucleotide encoding said hypoglycosylated PRRSV GP5
polypeptide variant. Promoters that can be used to drive
expression of the hypoglycosylated GP5 variant proteins
include, but are not limited to, the CMV (cytomegalovirus)
immediate early promoter, RSV (Rous sarcoma virus) long
terminal repeat promoter, and SV40 (Simian Virus 40) T-an
tigen promoter. In certain preferred embodiments, this pro
moter is a CMV promoter.
In still other embodiments, the isolated polynucleotide
expressing the hypoglycosylated GP5 variant protein com
prises a viral vector other than PRRSV. Viral vectors other

Example 1
10

15

Materials and Methods

Cells, media, and antibodies. The MARC-145 cells were

than PRRSV include, but are not limited to, vaccinia virus

vectors, a herpes simplex viral vectors, adenovirus vectors,
alphavirus vectors, and TGEV vectors. Such vectors are
described in various publications such as U.S. Pat. No. 7,041,
300 (for TGEV vectors) and U.S. Pat. No. 6,692,750 (for
alphavirus vectors).
Therapeutically Acceptable Carriers and Adjuvants
In practicing the invention, the hypoglycosylated GP5 vari
ant polypeptides or polynucleotides that encode hypoglyco
sylated GP5 variant polypeptides can be combined with
therapeutically acceptable carriers or excipients. Non limit
ing examples of such carriers include physiological saline or
other similar saline Solutions, proteins such as serum albumin
proteins, buffers such as carbonate, phosphate, phosphonate,
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6,977,245 and 6,406,705.

The use of other adjuvants that potentiate cellular immune
responses (i.e., T helper cell (Th..sub.1 and Th. Sub.2) Sub
population potentiators) is also contemplated. Such adjuvants
include but are not limited to interleukin 1 (IL-1). IL-2, IL4.
IL-5, IL6, IL-12, gamma interferon (g-IFN), cell necrosis
factor, MDP (muramyl dipeptide), immuno stimulant com
plex (ISCOM), and liposomes.
Administration of the composition can be accomplished by
Subcutaneous injection, intravenous injection, intradermal
injection, parenteral injection, intramuscular injection,
needle free injection, electroporation, oral delivery, intranasal
delivery, oronasal delivery, or any combination thereof.

propagated in Dulbecco's Modified Eagle's Medium
(DMEM) containing 10% fetal bovine serum (FBS) and 100
units of penicillin, 20 units of streptomycin and 20 units of
kanamycin per ml of growth medium. These cells were used
for RNA electroporation, virus infection, viral growth, and
plaque assays. The baby hamster kidney (BHK-21) cells were
maintained in Minimal Essential Medium (MEM) with Earl's
salt containing 5% FBS and the above mentioned antibiotics.
BHK-21 cells were used for transient expression of GP5
followed by either immunofluorescence assays (IFA) or
radiolabeling and immunoprecipitation experiments. All
cells were maintained at 37° C. and 5% CO2 environment.

35

or Tris based buffers, surfactants such as NP40 or Triton

X100, and a polyethylene glycol polymers. Any combination
of such carriers can be used in the compositions and methods
of this invention. A preferred carrier for compositions com
prising live or attenuated PRRSV viruses is dl-C-tocopherol
acetate at a concentration of between 50 to 100 mg/ml.
The use of adjuvants in compositions containing either the
hypoglycosylated GP5 variant polypeptides or polynucle
otides that encode hypoglycosylated GP5 variant polypep
tides is also contemplated. Such adjuvants are typically either
aqueous or oily in nature. Adjuvants that can be used include,
but are not limited to, aluminum hydroxide, Quil A, an alu
mina gel Suspension, mineral oils, glycerides, fatty acids,
fatty acid by-products, mycobacteria, and CpG oligodeoxy
nucleotides, or any combination thereof. Various types of
CpG adjuvants that can be used are described U.S. Pat. Nos.

The following example illustrates the construction of vari
ous PRRSV polynucleotides that encode various hypoglyco
sylated North American PRRSV GP5 polypeptide variants,
compositions including Such polynucleotides that are used to
elicit improved immune responses to a PRRSV antigen, and
methods of using the polynucleotides and compositions to
elicit an improved immune response in a pig to a PRRSV
antigen.

40

Rabbit polyclonal antibodies to PRRSV GP5 and M proteins
were kindly provided by Carl A. Gagnon (University of Que
bec, Montreal, Canada). The monoclonal antibody
(SDOW17) against nucleocapsid protein (N) was purchased
from National Veterinary Services Laboratories (NVSL,
Ames, Iowa, USA). Anti-mouse Alexa-488 was obtained
from Molecular Probes, Inc. (Eugene, Oreg., USA).
Genetic Manipulation of Plasmids Encoding GP5 and
PRRSV Infectious Clone
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The full-length PRRSV infectious cDNA clone (FL12:
SEQ ID NO:16) in pBR322 was digested with EcoRV and
Bst717 I restriction enzyme and the -4.9 kbp fragment
encompassing majority of ORF2, complete ORF3-7, and the
entire 3'UTR of PRRSV was cloned in pBR322 using the
same enzyme sites. This intermediate plasmid served as the
template for mutagenesis to introduce mutations at the poten
tial N-linked glycosylation sites (N34, N44, and N51) within
GP5 (FIG. 2). Mutagenesis was carried out using overlap
extension PCR with synthetic primers (Table 2) using stan
dard techniques.

55

TABLE 2

Primers and their sequences used in this study.
Primers
60 GP5-N34A-For

Nucleotide sequences
5

GCCAACAGCGCCAGCAGCTCTC 3'

(SEQ ID NO:18)
GP5-N44A-For

s' GTTGATTTACGCCTTGACGCTATG 3."

(SEQ ID NO:19)
65 GP5-N51A-For

5

GTGAGCTGGCTGGCACAGATTG 3."

(SEQ ID NO: 2O)

US 7,608,272 B2
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TABLE 2 - continued

Primers and their sequences used in this study.
Primers
GP5-N3.4/44A-For

Nucleotide sequences
s' GCCAACAGCGCCAGCAGCTCTCATCTTCA
GTTGATTTACGCCTTGACGCTATG 3."

(SEQ ID NO:21)
10

GP5-N44/51A-For

s' GTTGATTTACGCCTTGACGCTATGTGAGC
TGGCTGGCACAGATTG 3."

(SEQ ID NO: 22)
GP5-N3.4/51A-For

s' GCCAACAGCGCCAGCAGCTCTCATCTTCA

GTTGATTTACAACTTGACGCTATGTGAGCTGG
CTGGCACAGATTG 3'
(SEQ ID NO:23)

15

GP5-N34/44/51A-For 5' GCCAACAGCGCCAGCAGCTCTCATCTTCA

trols.

GTTGATTTACGCCTTGACGCTATGTGAGCTGG
CTGGCACAGATTG 3'
(SEQ ID NO:24)
PRRSW-13177 - For

5' CTACCAACATCAGGTCGATGGCGG 3."

(SEQ ID NO:25)
PRRSW-14473 - Rew

s' GTCGGCCGCGACTTACCTTTAGAG 3 '

(SEQ ID NO: 26)

25

Underlined codon sequences indicate the site of
mutation.

The PCR product was digested with BsrG I and BstE II
restriction enzymes and replaced back in the intermediate
plasmid. Clones containing the desired mutations were iden
tified and confirmed by sequencing. The entire coding region
of GP5 was sequenced to make sure that additional mutations
were not present in the clones. The EcoRV-Pac I fragment
from the intermediate plasmid containing mutations in the
GP5 coding region was moved back into the full-length
cDNA clone using the same restriction enzyme sites. The
GP5 coding region in the full length clones was again
sequenced with PRRSV specific internal primers to confirm
the presence of the mutations.
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Metabolic Radiolabeling and Analyses of Proteins
BHK-21 cells in six-well plates were infected with recom
binant vaccinia virus (VTF7-3) at an MOI of 3.0 and subse
quently transfected with bicistronic plasmid DNA encoding
wt or various mutant GP5 under T7 RNA polymerase pro
moter. DNA transfection was carried out using Lipo
fectamine2000TM as per manufacturer's protocol (Life Tech
nologies, USA). At 16 hrs post-transfection, cells were
washed twice with PBS and starved in methionine/cysteine
free DMEM for one hr and radiolabeled with 0.6 ml of

methionine/cysteine-free DMEM containing 100 uCi of

ExpreSS Protein Labeling Mix (NEN Life Sciences, Bos
35
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The wt GP5 and individual mutants were cloned in a bicis

tronic vector where the GP5 is the first cistron followed by
encephalomyocarditis virus (EMCV) internal ribosome entry
site (IRES) and M coding sequences (FIG. 1A). The full
length GP5 was also cloned in a CMV promoter driven vector
(pcDNA 3.0TM, Clontech Laboratories, Inc., Mountain View,
Calif., USA) for complementation studies. To this end, the
GP5 coding region was PCR amplified, cloned and
sequenced.
In Vitro Transcription and Electroporation
The full-length plasmids were digested with AclI and lin
earized DNA was used as the template to generate capped
RNA transcripts using the mMESSAGE mMACHINE Ultra
T7TM kit as per manufacturers (Ambion, Inc., Austin, Tex.,
USA) recommendations and as described earlier. The reac
tion mixture was treated with DNasel to digest the DNA
template and extracted with phenol and chloroform and
finally precipitated with isopropanol. The integrity of the in
vitro transcripts was analyzed by glyoxal agarose gel electro
phoresis followed by ethidium bromide staining.
MARC-145 cells were electroporated with approximately
5.0 g of in vitro transcripts along with 5.0 ug of total RNA
isolated from MARC-145 cells. About 2x 106 cells in 400 ul
of DMEM containing 1.25% DMSO were pulsed once using
Bio-Rad Gene Pulser XcellTM (Bio-Rad, Inc., Hercules,
Calif., USA) at 250V,950 uF in a 4.0 mm cuvette. The cells
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were diluted in normal growth media, plated in a 60-mm cell
culture plate. A small portion of the electroporated cells was
plated in a 24-well plate to examine expression of N protein at
48 hrs post-electroporation, which would indicate genome
replication and transcription. Once expression of N protein is
confirmed using indirect immunofluorescence assay (IFA),
the supernatant from bulk of the electroporated cells in
60-mm plate was collected at 48 hrs post-electroporation,
clarified and passed onto naive MARC-145 cells. The
infected cells were observed for cytopathic effect (CPE)
along with the expression of N protein using IFA. The super
natants from infected cells showing both CPE and positive
fluorescence were assigned to contain infectious virus. After
confirmation, the virus stock was grown and frozen at -80°C.
in Small aliquots for further studies. In all the experiments,
FL12 containing wt PRRSV genome and FL12pol-contain
ing polymerase-defective PRRSV genome were used as con

ton, Mass.) per ml of medium for three hrs. Following radio
labeling, the cells were washed in cold PBS three times and
cell extracts were prepared in 300 ul of radioimmunoprecipi
tation assay (RIPA) buffer (10 mM Tris-HCl pH 8.0, 150 mM
NaCl, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycho
late, and 1x protease inhibitor). The clarified cell extracts
were incubated overnight at 40 C with rabbit anti-GP5 or
anti-M protein antibody. A slurry of approximately 4.0 mg of
protein Asepharose (Pharmacia, Uppsala, Sweden) in 100 ul
RIPA buffer was added and further incubated for 2 hrs. The
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immunoprecipitated complexes were washed 3 times with
500 ul of RIPA buffer and used for further analysis.
For endoglycosidase H (Endo H) treatment, the immuno
precipitated complexes were resuspended in 20ll of 1x dena
turing buffer (0.5% SDS, 1.0% f-mercaptoethanol) and
boiled for 10 min. The supernatant was collected, adjusted to
1x G5 buffer (0.05 M sodium citrate pH 5.5) and incubated
for 16 hrs at 37°C. with 100 units of Endo H (New England
Biolabs, Beverly, Mass., USA). The undigested control
samples were processed similarly but no Endo H was added.
Following Endo H digestion, the samples were mixed with
equal volume of 2xSDS-PAGE sample buffer, boiled for 5
min and resolved by SDS-12% PAGE under denaturing con
ditions along with protein marker (Protein Plus Precision
Standard, Bio-Rad, Inc). The gel was fixed with 10% acetic
acid for 15 min, washed three times with water, treated with
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0.5M sodium salicylate for 30 min, dried and finally exposed
to X-ray film at -70° C. For peptide N-Glycosidase F (PN
Gase F) (New England Biolabs, Inc) digestion, immunopre
cipitated complexes were resuspended in 1x G7 buffer (0.05
M sodium phosphate pH 7.5, 1.0% NP-40) and digestion was
performed by incubating for 16 hrs at 37°C. with 2 units of
the enzyme. To examine synthesis of GP5 in the presence of
tunicamycin (Sigma, St. Louis, Mo.), transfected cells were

US 7,608,272 B2
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treated with 2.0 ug of tunicamycin per ml of medium for one
hr and radiolabeling was performed in the presence of the
drug for 3 hrs as above.
For obtaining radiolabeled extracellular virions or intrac
ellular virus expressed GP5, MARC-145 cells were infected
with wt or mutant PRRSVs. At 48 hrs post-infection, the cells
were starved for one hr and radiolabeled with 100 uCi of

22
serum. The mixtures were added to 96-well microtitration

plates containing confluent MARC-145 cells which had been
seeded 48 hrs earlier. After incubation for 24 hrs at 37°C. in

a humidified atmosphere containing 5% CO2, the cells were
5

fixed for 10 min with a solution of 50% methanol and 50%

10

acetone. After extensive washing with PBS, the expression of
N protein of PRRSV was detected with monoclonal antibody
SDOW17 using a 1:500 dilution, followed by incubation with
FITC-conjugated goat anti-mouse IgG (Sigma, St. Louis,
Mo., USA) at a 1:100 dilution. Neutralization titers were
expressed as the reciprocal of the highest dilution that inhib
ited 90% of the foci present in the control wells.
Experimental Inoculation of Pigs with GP5 Mutants and Wt

Express Protein Labeling Mix per ml of medium con

taining 90% methionine/cysteine free DMEM and 10% regu
lar DMEM for 24 hrs. Following labeling, the culture super

natant was harvested, cleared of cell debris and the

extracellular virions were pelleted at 100,000xg for 3 hrs at 4
C. The viral pellets were resuspended in 200 ul of RIPA
buffer, immunoprecipitated with anti-GP5 antibody and the
proteins were examined with or without Endo H treatment.
For immunoprecipitation of intracellular virus expressed
GP5, infection was carried as above and at 24 hrs post-infec
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tion, the cells were starved for one hr, radiolabeled as above

for 2 hrs prior to preparing cell extracts.
Viral Growth Kinetics and Plaque Assay

10-fold serial dilutions of individual viruses for one hr at 37°

C. The infected cell monolayer was washed with PBS and
overlaid with DMEM-5% FBS containing 0.8% Seaplaque
agarose (FMC Bioproducts, Rockland, Me. USA). After 96
hrs, the agarose plugs were removed and cell monolayer was
incubated with staining solution (20% Formaldehyde 9.0%
Ethanol, and 0.1% Crystal violet) for 30 min at room tem
perature. The cells were gently washed with water to remove
excess dye and air dried to examine and count the plaques.
Complementation of Virus Recovery by Expressing Wt GP5

were negative for anti-PRRSV antibodies as tested by ELISA
(Iddex Labs, Portland, Me...). Three pigs per group were
25
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Results
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transfected into the cells.

Serum-Neutralization (SN) Assays
The titer of PRRSV-neutralizing antibodies in a serum
sample was determined using the fluorescence focus neutral
ization assay described previously. Serial dilutions oftest sera
were incubated for 60 min at 37° C. in the presence of 200
TCID50 of the challenge virus, which consisted of either
FL12 (wt PRRSV) or any of the GP5 mutant encoding
viruses, FL-N34A, FL-N51A, and FL-N34/51A in Dulbec

co's modified Eagle's medium containing 5% fetal calf

sisted of 105 TICD50 diluted in 2 ml and administered intra

muscularly in the neck. The rectal temperatures of the inocu
lated animals were monitored for 15 days post-inoculation
(PI). Viremia was measured by regular isolation on MARC
145 cells at days 4, 7 and 14 PI. Serum samples were drawn
weekly for a total period of 49 days PI. The serum samples
were used to detect homologous and heterologous cross
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and used to infect naive MARC-145 cells. The infected

MARC-145 cells were examined at 48 hrs post-infection for
expression of N protein by IFA as described above. The
number of positive cells was counted to assign the number of
pseudo-particles produced in the Supernatant. The average
number of positive cells was calculated from three indepen
dent experiments and was presented as the number of pseudo
particles produced per microgram of invitro transcribed RNA

infected with either FL12 wt PRRSV or mutants FL-N34A,
FL-N51A, and FL-N34/51A. In all cases, the inoculum con

neutralization titers for each of the mutants and wt PRRSV.

in Trans

BHK-21 cells were transfected with pcDNA-GP5. At 40
hrs post-transfection, the cells were harvested and electropo
rated with capped in vitro transcripts derived from full-length
PRRSV cDNA encoding mutant GP5. The electroporated
cells were diluted with fresh media and plated in 6-well plate.
The supernatant from electroporated cells was collected at 48
hrs post-electroporation, centrifuged to remove cell debris

High titer stocks (obtained through 3 passages in MARC
145 cells) of the GP5 mutant viruses (FL-N34A, FL-N51A,
and FL-N34/51A) and the FL12 (wt PRRSV) were used to
infect young pigs. Twenty-one-day old, recently weaned pigs
were purchased from a specific-pathogen-free herd with a
certified record of absence of PRRSV infection. All animals

MARC-145 cells were infected with mutant or wt PRRSV

at an MOI of 3.0 PFU per cell and incubated at 370 C in an
incubator. At various time points post-infection, aliquots of
culture supernatants from infected cells were collected and
virus titer in the Supernatants was determined and expressed
by tissue culture infectious dose 50 per ml (TCID50/ml). The
viral growth kinetics was performed three times. To examine
the plaque morphology of mutant viruses, plaque assay was
performed using MARC-145 cells. Cells were infected with

PRRSV
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Expression and Characterization of PRRSV GP5
The GP5 of PRRSV strain 97-7895 has three putative gly
cosylation sites (N34, N44, and N51). To examine the glyco
sylation pattern of GP5, we first generated abicistronic vector
in which the coding regions of GP5 and M proteins flanking
the IRES from EMCV were placed under the control of T7
RNA polymerase promoter (FIG. 1A). The rationale for con
structing the bicistronic vector is that the GP5 and M proteins
are known (for LDV and EAV) or postulated (for PRRSV) to
interact with each other and that Such interactions may be
important for protein folding, glycosylation, intracellular
transport, and/or other biological activity of GP5.
Transient expression of GP5 and M by transfection of the
bicistronic plasmid followed by radiolabeling and immuno
precipitation with anti-GP5 antibody revealed two major pro
tein species. The protein species migrating with a mass of
-25.5 kDa is the fully glycosylated form of GP5 (FIG. 1B,
lane 2). Since each N-linked glycosylation adds -2.5 kDa of
molecular mass to a protein, this indicates that all three poten
tial glycosylation sites are possibly used for glycosylation of
GP5. The 19.0kDa protein species is the viral M protein since
it was also was immunoprecipitated with anti-M antibody
(lane 7). The results indicate that GP5 and M proteins interact
with each other in cells expressing both proteins. Upon treat
ment with Endo H, an enzyme that removes high-mannose
type oligosaccharide chains, the size of the GP5 was reduced
to ~18 kDa, whereas the size of the M protein remained
unchanged (lane 3). Treatment of GP5 with PNGase F (lane
4), an enzyme that removes all type Sugars from protein
backbone or synthesis of GP5 in the presence of tunicamycin
(lane 5) resulted in a protein that migrated with slightly faster
electrophoretic mobility than the protein with Endo-H treat
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ment. This is expected, since tunicamycin treatment or diges
tion with PNGase F would generate unglycosylated proteins
whereas Endo-H treatment would result in proteins that retain
N-acetylglucosamine residues at each of the N-linked glyco
Sylation sites. It is of note that a prominent protein species of
~30 kDa molecular mass was immunoprecipitated with
anti-Mantibody. The identity of this protein is not known but
it could be a cellular protein that interacts with the M protein.
The results from the above studies suggest that the ungly
cosylated and fully glycosylated forms of GP5 possess appar
ent molecular sizes of 18.0 kDa and 25.5 kDa, respectively. It
appears that all three potential glycosylation sites are used to
generate the fully glycosylated form of GP5. The glycan
moieties added to these sites are of high-mannose type since
they are sensitive to digestion by Endo H. In addition, the
results indicate that both unglycosylated and fully glycosy
lated forms of GP5 appear to interact with the M protein.
Analysis of N-Linked Glycosylation Sites Used for Glycosy
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MARC-145 cells while that of FL-N34/51A with double

mutations (N34/51A) was almost 1.5 log less than the wt
PRRSV (FIG. 3A). The RT-PCR amplification of RNA from
infected cells followed by nucleotide sequencing indicated
5
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virus recovery, repeated attempts to recover other mutant
viruses were unsuccessful. Although the growth kinetics of
overall yield of FL-N34A and FL-N51 A viruses containing
mutations at N34 and N51 was approximately one log less in

previously, we were able to recover pseudo-particles contain
ing two mutant full-length genomes (FL-N44A and FL-N34/
44A) (FIG. 3C). Each green fluorescing cell in the mutant
virus-infected culture represents one infectious pseudo-par
ticle. Since these particles contain only the functional wt GP5
on the envelope but contain the coding sequences for non
functional mutant GP5 in the genome, they cannot produce
infectious particles to spread to Surrounding cells. Multiple
attempts to recover pseudo-infectious particles with the other
mutant templates (FL-N44/51A, and FL-N31/44/51A) were
A quantitative estimation of the number of infectious
pseudo-particles produced from these experiments suggests
that approximately 1000 particles are produced per micro
gram of mutant RNA electroporated into the cells (FIG. 3D).
This is approximately 100 fold less than that obtained with
RNA encoding wt GP5. Production of such low levels of
infectious pseudo-particles could be due to the fact that only
about 5-10% of cells that expressed the wt GP5 received the
full-length transcripts as seen by the expression of the N
protein in these cells. It is also possible that low levels of
expression of wt GP5 in the transfected cells may have con
tributed to the low levels of production of these pseudo
virions.

N34, N51, and N34/51. However, under similar conditions of

the recovered viruses were similar to that of the wt virus, the

and used to infect naive MARC-145 cells to determine the

production of PRRSV pseudo-particles. If the pseudo-par
ticles are generated, one would then expect to observe expres
sion of the N protein in these infected MARC-145 cells. The
expression of N is only possible when naive MARC-145 cells
receive full-length encapsidated mutant RNA genome that
sets up replication following entry of the pseudo-particles

unsuccessful.

tious PRRSV was examined. Our results showed that infec

tious virus was readily recovered from the cells electropo
rated with full-length transcripts containing mutations at

mutant templates FL-N44A, FL-N31/44A, FL-N44/51A, and
FL-N31/44/51A, it is possible that mutations in GP5 coding
region may have affected some other functions of the RNA
templates, such as packaging of the genomic RNA into par
ticles. To address this, we examined whether cells expressing
wt GP5 in trans could support packaging of mutant RNA
templates that are otherwise defective in generating infec
tious PRRSV. BHK-21 cells transfected with pcDNA-GP5
were electroporated with in vitro transcripts and at 48 hrs
post-electroporation, the culture Supernatants were collected

into cells. Of all the mutants that could not be recovered

Thus, from the above mutational studies, it is clear that all

the three potential glycosylation sites are used for glycosyla
tion to generate fully mature PRRSV GP5. It appears that all
three glycosylation sites are modified by high-mannose type
glycan moieties.
Recovery of Infectious PRRSV Virus with GP5 Mutants
To assess the importance of N-linked glycosylation ingen
eration of infectious PRRSV, the coding regions of the mutant
GP5 proteins were inserted into the full-length cDNA clone.
Capped in vitro transcripts produced from the clones were
electroporated into MARC-145 cells and generation of infec

and no other mutations were detected in the entire GP5 region
(data not shown).
Viral plaque assay was performed on MARC-145 cells to
monitor the plaque phenotype of mutant viruses. The plaques
generated by wt PRRSV were clear and distinct while the
mutant viruses produced plaques that have different pheno
types. FL-N34A, FL-N51A and FL-N34/51 A viruses gener
ated plaques that were less distinct and many of the cells
within the plaque appeared normal (FIG. 3B, open arrow). In
addition, FL-N51A, FL-N34/51 A produced some plaques in
which the viruses failed to clear the cell monolayer (FIG.3B,
solid arrow). This data indicate that the recovered mutant
viruses are indeed less cytopathic as compared to wt PRRSV.
Since we were unable to recover infectious PRRSV with

lation of GP5

To more precisely determine whether all or some of the
potential N-linked glycosylation sites in GP5 are used for
addition of Sugar moieties, a series of mutants were generated
in the bicistronic plasmid where all three potential glycosy
lation sites N34, N44, and N51 (FIG. 2A) were altered to
alanines either individually or in various combinations (FIG.
2B). In plasmid-transfected cells, the proteins were radiola
beled and immunoprecipitated with anti-GP5 antibody. The
immune complexes were either left untreated or treated with
Endo Hand examined by SDS-PAGE. As can be seen from
the data presented in FIG. 2C, mutant GP5 proteins carrying
single mutations (N34A, N44A or N51A) migrated as
approximately 23.0 kDa protein species (lanes 4, 6 and 8.
arrowhead). Upon Endo H treatment, these proteins migrated
as ~18.0 kDa protein species (lanes 5, 7, and 9, respectively)
similar to the wt GP5 after Endo H treatment (lane 3). The
minor differences in electrophoretic mobility of the proteins
is most likely reflective of the fact that the wt protein would
retain all three N-acetylglucosamine residues following Endo
H treatment as compared to the single mutants that would
contain two such residues. The double mutants (N34/44A,
N44/51A and N34/51A) produced protein species that
migrated close to -20.5 kDa protein (lanes 10, 12 and 14) and
upon Endo H treatment, the size of the proteins was reduced
to 18.0 kDa (lanes 11, 13, and 15). The triple mutant (N34/
44/51A) generated a protein that migrated as 18.0kDa protein
(lane 16) and was resistant to Endo H digestion (lane 17).

that these viruses are stable, contained the desired mutations
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Examination of GP5 Incorporated into Mutant Viruses and
Those Expressed in Infected Cells
To determine the nature of GP5 protein incorporated into
infectious virions produced from transfected cells, we gener
ated radiolabeled PRRSV from cells infected with wt and
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mutant viruses. The extracellular virions present in the cul
ture supernatant were pelleted by ultracentrifugation and GP5
present in these virions was examined by immunoprecipita
tion using anti-GP5 antibody and subsequent electrophoretic
analysis. Results show the wt GP5 incorporated into virions
migrated as a broadly diffuse band of ~25-27 kDa protein
species (FIG. 4A, lane 1), which is partially resistant to Endo
H digestion (lane 2). Mutant GP5 (N34A and N51A) incor
porated into virions were sensitive to Endo H. Based on the
size of the products generated following Endo H digestion, it
appears that only one glycan moiety in these single site
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clearly suggests that the removal of one, and particularly two,
of the glycan moieties increases the accessibility of the neu
tralizing epitope to specific antibodies. These results appear
to indicate the presence of significant amount of PRRSV
neutralizing antibodies in the wt PRRSV-infected convales
cent sera that would otherwise be undetectable because of the

typical use of wt PRRSV containing fully glycosylated GP5
in SN assays.
Effect of alteration of glycosylation pattern of PRRSV GP5 on the
ability of the infectious virion to react with neutralizing antibodies.
Numbers in Table 3 correspond to the inverse end point dilution
showing neutralization (SN endpoint).

mutants is sensitive while the other is resistant. In contrast,

the double mutant GP5 (N43/52A) was resistant to Endo H.
Furthermore, Endo H digestion of GP5 from mutant viruses
also produced very small amounts of GP5 protein backbone,
indicating that these viruses incorporate GP5 proteins that
contain Endo H-resistant as well as Endo H-sensitive glycan

TABLE 3

10

15

Serum from animals

infected with 10

moieties.

TCIDso of wt PRRSV
FL12

Since in cells transfected with the bicistronic vector, the wt

as well as the mutant GP proteins were completely Endo H
sensitive (FIGS. 1 and 2), we were surprised by the observa
tion that GP5 on PRRS virions contained largely Endo H

Animal No.
Animal No.
Anirnal No.

cells infected with wt or mutant PRRSV were radiolabeled,

25 Animal No.

from that observed in cells expressing both GP5 and M pro
teins (FIGS. 1 and 2). These results indicate that other viral
proteins may play a role in further modification of glycans on
GP5. Influence of hypoglycosylation of GP5 on PRRSV’s
ability to be neutralized by specific antibodies.
The level of glycosylation of viral glycoproteins that are
involved in the interaction with viral receptors is known to
affect the ability of virions to react with virus-neutralizing
antibodies. To test whether this phenomenon occurs in the
case of PRRSV, the PRRSV GP5 mutants with altered gly
cosylation patterns (FL-N34A, FL-N51A and FL-N34/51A)
were compared with PRRSV wt (FL12) in their ability to be
neutralized by convalescent antisera. For this, we used con
Valescent antisera (47 days p.i.) from 4 animals that had been
infected with wt PRRSV. Similar doses (2,000 TCID50) of
infectious PRRSV GP5 mutants (FL-N34A, FL-N51A and
FL-N34/51A) as well as of the infectious clone-derived wit
PRRSV (FL12) were used as challenge virus in serum-neu
tralization assays following our standard assay protocol and
the set of 4 anti-wt PRRSV (FL12) sera used as reference.
Table 3 shows the different end-point serum neutralizing
titers obtained. Normally, a PRRSV wit-convalescent serum
sample collected at 47-54 days p.i. contains moderate levels
of wt PRRSV neutralizing activity (1:8 to 1:32, Tables 3 and
4), reflecting the relatively weak and tardy character of the
neutralizing antibody response that is typical of infections
with wt PRRSV. However, the use of hypoglycosylated
PRRSV mutants (which lack one or two glycan moieties on
the GP5 ectodomain) as challenge virus in the SN assays
seem to have significantly enhanced the end-point of the
reference Sera, with end-point titer enhancement ranging
from six to twenty-two fold (Table 3). This observation

FLN34A

FL-N51A

FL-N34.
51A

1:32

1:256

1:256

1:32,768

1:8

1:64

1:256

1:16,384

1:16

ND

1:128

1:2,048

1:8

ND

1:64

1:2,048

11346(47 days pi)

the protein are also synthesized in infected cells, MARC-145

what is observed for virion-associated GP5, it is different

Wt
PRRSV(FL12)

11404(47 days pi)

resistant forms. To examine if the Endo H resistant forms of

GP proteins were immunoprecipitated with anti-GP5 anti
body and analyzed by electrophoresis with or without Endo H
digestion. Results of Such an experiment are shown in FIG.
4B. Majority of wt GP5 contained Endo H-resistant glycans
at all three sites (lanes 2 and 3), whereas the two single
mutants contained Endo H-resistant glycans only at one site
(lanes 4-7). Some of the glycan moieties in the double mutant
are resistant while others are sensitive to Endo H (lanes 8 and
9). Although the pattern of Endo H-resistance is similar to

PRRSV strain used as challenge for SN test

11457(47 days pi)
11407(47 days pi)
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Influence of Hypoglycosylation of GP5 on PRRSV’s Ability
to Induce Neutralizing Antibodies In Vivo
One remarkable effect that has been reported where carbo
hydrate removal from a viral envelope glycoprotein leads to
production of high titers of neutralizing antibodies against the
mutant virus when this mutant is used for in vivo inoculation

35

40

of the host; in some cases also inducing higher titers of anti
body to the wt virus than the wt virus itself. We infected
groups of pigs with identical doses of either the wt PRRSV
FL12 or of each of the mutants with altered glycosylation
patterns. Interestingly, clinical/virological assessment of the
infection by evaluation of rectal temperature and evaluation
of viremia at days 4, 7 and 10 p.i. indicated a similar pattern
of infection in all groups as previously described for FL12
without evidence of virulence attenuation or exacerbation for
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either of the mutants (data not shown). However, the sequen
tial sampling of serum from these animals throughout a
period of 48 days indicated pronounced differences between
the wt PRRSV and the mutants in their kinetics of induction

50

55

of a PRRSV-neutralizing antibody response (Tables 4A and
4B). The mutants developed an early and more robust
homologous neutralizing antibody response than that devel
oped by wt PRRSV, to the point where, in the case of the
mutants, the characteristically sluggish and meager nature of
PRRSV-neutralizing antibody response appears to have been
corrected (Table 4B). The kinetics of appearance of mutant
homologous neutralizing antibodies (Table 4B) indicate a
more regular neutralizing antibody seroconversion consistent
with that described for other viral infections such as influenza

60

or Pseudorabies virus but not for PRRSV. Of utmost impor
tance is the fact that the infection with GP5 glycosylation
mutants induced a wt PRRSV-specific neutralizing antibody
response that is significantly higher than the response with the
wt PRRSV itself. The mutant viruses FL-N34 and FL-N51A
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induced five-fold higher (p<0.05) levels of neutralizing anti
body titer against wt PRRSV than the wt PRRSV itself while
the mutant FL-N34/51 induced six-fold higher (p<0.01) titer
of wt PRRSV-neutralizing antibodies than wt PRRSV itself
(Table 4B).
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TABLE 4A

Group

Neutralizing antibody activity against
FL12 at different times PI (days PI

infected with

O

14

21

48

1.0%
1.O
1.O
1.O

1.O
1.O
1.O
1.O

3.2
4.0
4.0
S.O

25.4
128.0
128.0
1613

Wt PRRSVFL-12
FL-N34A
FL-NS1A
FL-N34,51A

Table 4A. Effect of alteration of glycosylation pattern of PRRSV GP5 on the
ability of the PRRSV strains to induce neutralizing antibodies to the wt
PRRSV (4A) or to the infecting, homologous strain (4B) (*) Numbers in
Table 4A and B correspond to geometric mean of the SN end-point for the
group (n = 3).

10

sensitive to Endo H. These data are consistent with the inter
15

TABLE 4B

Group

End-point titer against the homologous
infecting strain at different PI periods

infected with

O

14

21

48

Wt PRRSVFL-12
FL-N34A
FL-NS1A

1.O
1.O
1.O
1.O

1.O
4.0
4.0
4.0

3.2
128
128
64

25.4
8,192
2,048
4,096

FL-N34,51A
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Discussion

In the present study, we examined the influence of glyco
sylation of GP5 of PRRSV in recovery of infectious virus, its
role in the ability of the mutant viruses to be neutralized by
antibodies, and in inducing neutralizing antibodies in vivo.
We have found that all three potential glycosylation sites
(N34, N44, and N51) in GP5 are used for addition of glycan
moieties. Our results reveal that glycan addition at N44 site is
most critical for recovery of infectious virus. Furthermore,
our results show that PRRSV containing hypoglycosylated
forms of GP5 are exquisitely sensitive to neutralization by
antibodies and that the mutant viruses induce significantly
higher levels of neutralizing antibodies not only to the
homologous mutant viruses but also to wt PRRSV.
Confirmation that all three potential N-linked glycosyla
tion sites are used for glycan addition in GP5 was provided by
using mutants with alterations at single or multiple sites (FIG.
2). Biochemical studies showed that the PRRSV GP5 protein
when coexpressed with M protein in transfected cells, con
tains Endo H sensitive high-mannose type glycans. The
observation that majority of GP5 incorporated into virions is
resistant to Endo H (FIG. 4A) whereas GP5 expressed in the
presence of M protein in transfected cells is fully Endo H
sensitive, is intriguing. It is possible that GP5 when expressed
in the presence of M protein in transfected cells, accumulates
mostly in the ER or in the cis-Golgi region and therefore
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pretation that wt as well as mutant PRRSV virions incorpo
rate a mixed population of GP5 molecules that contain dif
ferent glycan moieties at different sites. Previous studies
demonstrating incorporation of differentially glycosylated
forms of GP5 into wt PRRSV virions further strengthens our
interpretation. From the pattern of Endo H sensitivity of GP5
incorporated into the virions, it is tempting to speculate that
N44 site may contain the Endo H resistant glycans, although
some GP5 molecules with Endo H sensitive glycans at this
site were incorporated into the virions. Whether this unusual
pattern of glycans at various sites in GP5 and incorporation of
various forms of GP5 into virions has any relevance to the
pattern of immune response seen in PRRSV infected animals
remains to be investigated.
In a recent study, it was shown that of the two N-linked
glycosylation sites (N46 and N53) in GP5 of Lelystad
PRRSV, glycosylation of N46 residue was strongly required
for virus particle production. Infectious virus yield was
reduced by approximately 100-fold with mutation at N46.
Our results suggest that glycan addition at N44 (for North
American PRRSV) is absolutely essential for recovery of
infectious PRRSV. It is possible then that the European and
North American isolates of PRRSV may somewhat differ in
their requirements for N-linked glycosylation for production
of infectious viruses. In this regard, it is of note that the
Lelystad virus contains only two N-linked glycosylation sites
whereas the North American isolate we have used in this
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remains Endo H sensitive. However, in PRRSV-infected

cells, GP5 may interact with additional viral proteins and the
transport of GP5 beyond ER or cis-Golgi is facilitated
through formation of complexes with the other viral proteins.
Consistent with this interpretation, we have observed that in
wt or mutant PRRSV-infected cells, GP5 protein is also resis
tant to Endo H. We suggest that GP5, which is synthesized in
the ER in infected cells, is transported to the medial- and/or
trans-Golgi regions where majority of GP5 molecules acquire
Endo H resistance prior to being incorporated into PRRSV
virions. Several studies with arteriviruses including PRRSV
suggest that GP5 and M proteinform heterodimer, which may
play a key role in viral infectivity. In EAV and LDV, direct
interaction of GP5 and M protein through formation of dis
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ulfide bridges have been demonstrated. Such interactions
may occur prior to further processing of N-linked oligosac
charide side chains, presumably before GP5 is transported out
of the ER or the cis-Golgi compartment.
It is interesting to note that the pattern of Endo H resistance
of GP5 incorporated into wt and mutant virions is different.
While the majority of GP5 molecules in wt PRRSV were
Endo H resistant, most of GP5 molecules in the single site
mutant virions (FL-N34A and FL-N51A) were Endo H sen
sitive (FIG. 4A). Furthermore, of the two glycans moieties in
these mutants, only one was sensitive while the other was
resistant. The double mutant (FL-N34/51A) virion also incor
porated GP5 that contained glycans, some of which were also
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study contain three such sites.
The GP5 is the most important glycoprotein of PRRSV
involved in the generation of PRRSV-neutralizing antibodies
and protective immunity. Our results reveal that the absence
of glycans at residues 34 and 51 in the GP5 ectodomain, while
generating viable PRRSV mutants, enhance both the sensi
tivity of these mutants to neutralization by antibodies as well
as the immunogenicity of the nearby neutralization epitope.
The immediate effect of the absence of glycans in GP5 of
mutant PRRSVs has been the increased sensitivity of the
viruses to neutralization by convalescent Sera from pigs
infected with wt PRRSV (Table 3). Studies with HIV-1 and
SIV have shown that acquisition or removal of glycans in the
variable loops of gp160 modify their sensitivity to neutraliza
tion. Therefore, it has been postulated that glycans play at
least two types of essential roles during viral envelope glyco
protein biosynthesis. In one case, lack of glycans entails
defects of the glycoprotein and thus, in the overall viability of
the viral strain. We postulate that glycans at N44 of PRRSV
GP5 serve a similar role. In the second case, the glycans
potentially serve to shield viral proteins against neutralization
by antibodies. For PRRSV GP5, glycans at N34 and N51 may
have a similar role. In the case of HIV. “glycan shielding is
postulated to be a primary mechanism to explain evasion from
neutralizing immune response, thus ensuring in vivo persis
tence of HIV. This invites to draw some parallel comparisons
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with the PRRSV. Infection with PRRSV, which is known to

persist for several months in individual animals, presents an
unusual behavior in terms of induction of virus-specific neu
tralizing immune response. It is well established that animals
infected with PRRSV usually take longer than normal time to
establish a detectable PRRSV-neutralizing antibody
response. Once established, this PRRSV-neutralizing
response is weak, and varies significantly from animal to
animal. The delay in neutralizing antibody response has been
postulated to be due to the presence of a nearby immunodomi
nant decoy epitope (amino acid positions 27 to 30), which
evokes a robust, early, non-protective immune response that
masks and/or slows the response to the neutralizing epitope
(amino acid position 37 to 45) (26, 38). While this being a
plausible explanation for the atypical character of the
PRRSV-neutralizing antibody response, it remains to be
tested. In our laboratory, deletion of the decoy epitope has
consistently proven lethal to the recovery of infectious
PRRSV (Ansari et al., unpublished data), thus making it
difficult to test this hypothesis.
It is possible that an alternative or complementary mecha
nism to explain the peculiar nature of the PRRSV-neutraliz
ing response could be envisioned by the “glycan shielding
phenomenon proposed for HIV and SIV. The use of mutant
PRRSVs lacking one or two glycan moieties in our studies
provides evidence for the first time the presence of large
amounts of PRRSV neutralizing antibodies in the sera of wt
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diverse unrelated PRRSV Strains.
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model that we used for inoculation with PRRSV, we were not

able to detect pathogenic differences between any of the
mutant PRRSVs and the wt PRRSV, although we limited our
observations to temperature and viremia measurements. It is
possible that under different experimental conditions (i.e., in
a pregnant sow model). Some alterations in pathogenicity of
these mutant PRRSVs might be observed. It is not known
whether the finding of naturally occurring hypoglycosylated
PRRSV strains is a common occurrence, although previous
reports have suggested their presence.
A remarkable observation in our experiments has been that
the GP5 mutants, when infecting pigs in Vivo, can outperform
the wt PRRSV in their ability to mount a sizable wt PRRSV
neutralizing response at late phases of infection (Table 4A).
In a parallel scenario, we have observed not only higher
neutralizing titers against homologous PRRSV mutants but
also sizable titers against wt PRRSV (Table 4A). In addition,
the response occurred earlier, with neutralizing titers detect
able at 14 days p.i., an observation not typically noted with wit
PRRSV infection (Table 4B). The increased neutralization of

Example 2
Identification of N-Linked Glycosylation Sites in
North American and European PRRSV. Isolates

PRRSV-infected animals that were otherwise undetectable

because of the use of wt PRRSV in the SN assays. The
PRRSV-neutralizing antibodies, while present in the hosts
response, are unable to react with the infecting wt PRRSV
virions due to the blocking or shielding of the neutralizing
epitope by the glycan moieties on GP5.
One important precedent for neutralization escape by gly
cosylation of glycoproteins in arteriviruses has been
described for lactate dehydrogenase-elevating virus (LDV).
LDV is highly resistant to antibody neutralization due to the
heavy glycan shielding of their major glycoprotein, VP-3,
however, certain naturally occurring strains of LDV are
highly susceptible to neutralization, due to loss of two glyco
sylation sites on the ectodomain of the VP-3. Interestingly,
this neutralization-sensitive phenotype correlates with a high
degree of neurotropism in the host acquired by these easily
neutralizable LDV strains. Such neuropathogenicity
enhancement probably reflects the facilitation of interaction
of the viral glycoproteins with receptors in neural cells, pos
sibly due to the absence of glycan shielding. In the young pig
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wt PRRSV by sera from pigs infected with the PRRSV
mutants Suggests that glycans were masking neutralizing
epitope(s) that do not induce neutralizing antibodies when
glycans are present. This observation has great significance
on the design of better, more efficacious PRRSV vaccines,
Suggesting that new, rationally-designed vaccines should
carry modifications in the glycosylation pattern of GP5 in
order to enhance the production of neutralizing antibodies. In
addition, it will be important to study the effects that this
removal of carbohydrates from immunologically prominent
glycoproteins of PRRSV may have on increasing SN titers
not only to the homologous immunizing strain but also to
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To identify N-linked glycosylation sites corresponding to
asparagine 34 or asparagine 51 in a reference GP5 protein of
SEQID NO:1 that can be inactivated and used in the methods
of this invention, the GP5 proteins of either a desired North
American PRRSV isolate (FIG. 5) or a European PRRSV
isolate (FIG. 6) are aligned with reference GP5 protein of
SEQ ID NO: 1 (North American strain NVSL 97-7895). In
this example, the alignments were created with the MegA
lignTM program from DNASTAR, Inc. (Madison, Wis., USA)
using the Jotun-Hein method of alignment (Hein, J. J. In
Methods in Enzymology, Vol. 183: pp. 626-645, 1990). Mul
tiple sequence alignment parameters were a gap penalty of 11
and a gap length penalty of 3. For pairwise comparisons, a
Ktuple value of 2 was used.
In FIG. 5, it is clear that the N-linked glycosylation site
corresponding to asparagine 51 of the reference GP5 protein
of SEQID NO:1 present in all of the North American PRRSV
isolates shown and comprises the N-linked glycosylation site
“NGT. This N-linked glycosylation site can be inactivated
by Substituting codons encoding other amino acid residues
Such as glutamine or alanine for asparagine 51 in the corre
sponding polynucleotide sequence. In these instances, the
corresponding amino acid sequence in the hypoglycosylated
North American PRRSV GP5 protein variant would comprise
the sequences such as “QGT”, “AGT', or “XGT, where X is
any amino acid other than asparagine. These or other
hypoglycosylated variants of the North American PRRSV
isolates where N-linked glycosylation site corresponding to
asparagine 51 is inactivated can also be combined with other
hypoglycosylated GP5 variants where other N-linked glyco
Sylation sites are inactivated.
It is also clear from FIG. 5, that the N-linked glycosylation
site corresponding exactly to asparagine 34 of the reference
GP5 protein of SEQID NO:1 is present in only certain North
American PRRSV isolates. More specifically, the GP5 pro
teins of North American PRRSV isolates IAF-BAJ (SEQ ID
NO:3), 94-3182 (SEQID NO:7), and 94-287 (SEQID NO:8)
contain the N-linked glycosylation site corresponding exactly
to asparagine 34 of the reference GP5 protein of SEQ ID
NO:1 and comprises the N-linked glycosylation site “NSS'.
This N-linked glycosylation site of SEQ ID NO:3, 7, and 8
can be inactivated by Substituting codons encoding other
amino acid residues such as glutamine or alanine for aspar
agine 34 in the corresponding polynucleotide sequence. In
these instances, the corresponding amino acid sequence in the
hypoglycosylated North American PRRSV GP5 protein vari
ant would comprise the sequences such as “QSS', 'ASS, or
“XSS, where X is any amino acid other than asparagine.
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N-linked glycosylation site corresponding to asparagine 51 is
inactivated can also be combined with other hypoglycosy
lated GP5 variants where other N-linked glycosylation sites

In other North American PRRSV isolates that lack the

N-linked glycosylation site corresponding exactly to aspar
agine 34 of the reference GP5 protein of SEQID NO:1, other
N-linked glycosylation sites located at residue 30 (FIG. 5
“NAS” in SEQID NO:2, 3, 4, 6, 7, 8, 9, 11, 13), and residue
33 (FIG. 5 “NNS” in SEQID NO:3, 8: “NSS” in SEQ ID
NO:6, 10, “NDS” in SEQID NO:11, 13) can also be inacti
vated. In other words, N-linked glycosylation sites in other
North American isolates located at amino acid positions cor
responding to residues 30 and 33 of the reference GP5 protein
of SEQ ID NO:1 can also be inactivated and used in the

are inactivated.

In view of the foregoing, it will be seen that the several
advantages of the invention are achieved and attained.
The embodiments were chosen and described in order to
10

best explain the principles of the invention and its practical
application to thereby enable others skilled in the art to best
utilize the invention in various embodiments and with various

methods of this invention.

modifications as are Suited to the particular use contemplated.

In FIG. 6, it is clear that the N-linked glycosylation site
corresponding to asparagine 51 of the reference GP5 protein
of SEQID NO:1 is also present in a representative European
PRRSV isolate and comprises the N-linked glycosylation site
“NGT. This N-linked glycosylation site can be inactivated
by Substituting codons encoding other amino acid residues
Such as glutamine or alanine for asparagine 51 in the corre
sponding polynucleotide sequence. In these instances, the
corresponding amino acid sequence in the hypoglycosylated
European PRRSV GP5 protein variant would comprise the
sequences such as “QGT, “AGT', or “XGT, where X is any
amino acid other than asparagine. These or other hypoglyco
sylated variants of the European PRRSV isolates where

AS Various modifications could be made in the construc
tions and methods herein described and illustrated without
15

departing from the scope of the invention, it is intended that
all matter contained in the foregoing description or shown in
the accompanying drawings shall be interpreted as illustrative
rather than limiting. Thus, the breadth and scope of the
present invention should not be limited by any of the above
described exemplary embodiments, but should be defined
only in accordance with the following claims appended
hereto and their equivalents.
A variety of patent and non-patent references are disclosed
herein, each of which is expressly incorporated herein by
reference in their entirety.

SEQUENCE LISTING
<16 Oc NUMBER OF SEO ID NOS: 26
<21 Oc SEO ID NO 1
<211 LENGTH: 2OO
<212 TYPE PRT

ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 1

Met Lieu. Gly Arg Cys Lieu. Thir Ala Gly Cys Cys Ser Arg Lieu.
1.
Luell
2O

5

Trp. Cys Ile Wall

Pro Phe
25

Luell Ser
15

Phe Ala Ala Luell Wall ASn Ala Asn

Ser Asn. Ser Ser Ser His Lieu. Glin Lieu. Ile Tyr Asn Luell Thir Lell
35
4O
45

Glu

Lieu. Asn Gly. Thir Asp Trp Lell Lys Asp Llys Phe Asp Trp Ala Wall

SO

55

60

Glu Thir Phe Wall Ile Phe Pro Wall Lell Thir His Ile Wall Ser
65

Tyr Gly

70

Ala Lell Thir Thr Ser His Phe Lell Asp Thir Wall Gly Luell Wall Thir Wall
85

90

Ser Thir Ala
OO

Gly

Phe

Tyr

95

His

Gly Arg

Wall Luell Ser Ser Ile

O5

10

Val Cys Ala Lieu.

Ala Lieu. Ile

Wall Ile Arg Lieu Ala

Asn Cys Met Ser T

Arg

Arg

Thir Asn. Phe

Lieu. Asp Thir Lys

Arg Lieu. Tyr Arg T

Arg

Ser Pro Wall Ile
16 O

Glu Lys Gly Gly

Wall Glu Wall Glu

His Luell

Arg Val Val Lieu.

Gly Ser Val Ala T

Pro

Ser

le

Asp Lieu.

Luell Thir

Wall

US 7,608,272 B2
33

34
- Continued

Ser Ala Glu Gln Trp Gly Arg Lieu
195

<210

2 OO

SEQ ID NO 2

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 2

Met Leu Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Gln Leu Pro Phe
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser
2O

25

3O

Ser Ser Ser Ser Ser Gln Leu Glin Ser Ile Tyr Asn Lieu. Thir Ile Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Lys Asn. Phe Asp Trp Ala Val
SO

55

6O

Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Ala Val Gly Lieu. Ile Thr Val
85

9O

95

Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Val Tyr
OO

OS

1O

Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu. Thr
15

2O

25

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
3O

35

4O

Lieu. Lieu. Asp Ser Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

SO

55

160

le Glu Lys Gly Gly Llys Val Glu Val Asp Gly His Lieu. Ile Asp Lieu
65

70

7s

Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Lys Val
8O

85

90

Ser Ala Glu Gln Trp Cys Arg Pro
95

<210

2 OO

SEQ ID NO 3

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 3

Met Leu Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Gln Leu Pro Phe
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser
2O

25

3O

Asn Asn Ser Ser Ser Gln Leu Glin Ser Ile Tyr Asn Lieu. Thir Ile Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Lys Asn. Phe Asp Trp Ala Val
SO

55

6O

Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu. Ile Thr Val
85

9O

95

Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Val Tyr
1 OO

105

11O
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36
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Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu. Thr
15

12O

125

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
3O

135

14 O

Lieu. Lieu. Asp Ser Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

150

155

160

le Glu Lys Gly Gly Llys Val Glu Val Asp Gly His Lieu. Ile Asp Lieu
65

17O

17s

Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Lys Val
8O

185

190

Ser Ala Glu Gln Trp Cys Arg Pro
95

<210

2 OO

SEQ ID NO 4

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 4

Met Leu Gly Lys Cys Lieu. Thr Val Gly Tyr Cys Ser Gln Leu Pro Phe
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser
2O

25

3O

Ser Thr Ser Ser Ser His Leu Gln Lieu. Ile Tyr Asn Lieu. Thir Ile Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn. Glu, Llys Phe Asp Trp Ala Val
SO

55

6O

Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu Val Thr Val
85

9O

95

Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr
OO

OS

1O

Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu Val
15

2O

25

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
3O

35

4O

Lieu. Lieu. Asp Thir Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

SO

55

160

Val Glu Lys Arg Gly Llys Val Glu Val Gly Gly His Lieu. Ile Asp Lieu
65

70

7s

Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Arg Val
8O

85

90

Ser Ala Glu Gln Trp Gly Arg Pro

<210

SEQ ID NO 5

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 5

Met Leu Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Gln Leu Pro Phe
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Phe Cys Phe Val Ala Lieu Val Asn Ala Asn
2O

25

3O
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Thr Asp Ser Ser Ser His Leu Gln Lieu. Ile Tyr Asn Lieu. Thir Ile Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Asp Llys Phe Asp Trp Ala Val
SO

55

6O

Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu. Ile Thr Val
85

9O

95

Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr
OO

OS

1O

Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Ala Ile Arg Lieu. Thr
15

2O

25

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
3O

35

4O

Lieu. Lieu. Asp Thir Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

SO

55

160

le Glu Arg Glin Gly Llys Val Glu Val Glu Gly His Lieu. Ile Asp Lieu
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Arg Val
Ser Ala Glu Arg Trp Gly Arg Pro
95

2 OO

<210 SEQ ID NO 6
<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 6

Met Lieu. Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Arg Lieu Pro Phe
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser
2O

25

3O

Asn Ser Ser Ser Ser His Leu Gln Lieu. Ile Tyr Asn Lieu. Thir Ile Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asp Llys Llys Phe Asp Trp Ala Val
SO

55

6O

Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu. Ile Thr Val
85

9O

95

Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr
OO

OS

1O

Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu. Thr
15

2O

25

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
3O

35

4O

Lieu. Lieu. Asp Thir Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

SO

55

160

le Glu Lys Arg Gly Llys Val Glu Val Glu Gly Glin Lieu. Ile Asp Lieu
65

70

7s

Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Ile Thir Lys Val
8O

85

Ser Ala Glu Gln Trp Gly Arg Pro

90
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195

<210

2 OO

SEQ ID NO 7

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 7

Met Lieu. Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Arg Lieu Pro Phe
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Val Lieu Val Asn Ala Ser
2O

25

3O

Pro Asn Ser Ser Ser His Leu Gln Lieu. Ile Tyr Asn Lieu. Thir Ile Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Ala Arg Phe Asp Trp Ala Val
SO

55

6O

Glu Thr Phe Val Ile Phe Pro Val Val Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu Val Thr Val
85

9O

95

Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr
OO

OS

1O

Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu Ala
15

2O

25

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
3O

35

4O

Lieu. Lieu. Asp Thir Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

SO

55

160

le Glu Lys Arg Gly Llys Val Glu Val Glu Gly His Lieu. Ile Asp Lieu
Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Arg Val
Ser Ala Glu Gln Trp Cys Arg Pro
95

<210

2 OO

SEQ ID NO 8

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 8

Met Leu Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Gln Leu Pro Phe
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser
2O

25

3O

Asn Asn. Ser Ser Ser His Lieu. Glin Lieu. Ile Tyr Asn Lieu. Thir Ile Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Asp Llys Phe Asp Trp Ala Val
SO

55

6O

Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu. Ile Thr Val
85

9O

95

Ser Thr Ala Gly Tyr Tyr His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr
1 OO

105

11O

Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu Ala
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15

12O

125

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
3O

135

14 O

Lieu. Lieu. Asp Thir Lys Gly Arg Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

150

155

160

le Glu Lys Lys Gly Llys Val Glu Val Glu Gly Glin Lieu. Ile Asp Lieu
65

17O

17s

Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Ile Thir Arg Val
8O

185

190

Ser Ala Glu Gln Trp Gly Arg Pro
95

<210

2 OO

SEQ ID NO 9

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 9

Met Leu Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Gln Leu Pro Phe
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Lieu Val Asn Ala Ser
2O

25

3O

Ser Ser Ser Ser Ser Gln Leu Glin Ser Ile Tyr Asn Lieu. Thir Ile Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu. Asn Lys Asn. Phe Asp Trp Ala Val
SO

55

6O

Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Ala Val Gly Lieu. Ile Thr Val
85

9O

95

Ser Thr Ala Gly Tyr Tyr His Gly Arg Ser Val Lieu Ser Ser Val Tyr
OO

OS

1O

Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu. Thr
15

2O

25

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
3O

35

4O

Lieu. Lieu. Asp Ser Lys Gly Llys Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

SO

55

160

le Glu Lys Gly Gly Llys Val Glu Val Asp Gly His Lieu. Ile Asp Lieu
65

70

7s

Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Lys Val
Ser Ala Glu Gln Trp Cys Arg Pro
95

<210

2 OO

SEQ ID NO 10

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 10

Met Lieu. Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Glin Lieu. Lieu. Phe
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Ser Trp Phe Val Ala Leu Val Ser Ala Ser
2O

25

3O

Asn Ser Ser Ser Ser His Lieu. Glin Lieu. Ile Tyr Asn Lieu. Thir Lieu. Cys
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35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu Ala Asp Llys Phe Asp Trp Ala Val
SO

55

6O

Glu Thr Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu Val Thr Val
85

9O

95

Ser Thr Ala Gly Phe His His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr
OO

OS

1O

Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu Ala
15

2O

25

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
3O

35

4O

Lieu. Lieu. Asp Thir Lys Gly Arg Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

SO

55

160

le Glu Lys Gly Gly Llys Val Glu Val Glu Gly His Lieu. Ile Asp Lieu
65

70

7s

Lys Arg Val Val Lieu. Asp Gly Ser Val Ala Thr Pro Ile Thir Arg Val
Ser Ala Glu Gln Trp Gly Arg Pro

<210

SEQ ID NO 11

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 11

Met Lieu. Glu Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Arg Lieu. Lieu. Ser
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Val Lieu Ala Asn Ala Ser
2O

25

3O

Asn Asp Ser Ser Ser His Lieu. Glin Lieu. Ile Tyr Asn Lieu. Thir Lieu. Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu Ala Asn Llys Phe Asp Trp Ala Val
SO

55

6O

Glu Ser Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Ala Leu Val Thr Val
85

9O

95

Ser Thr Ala Gly Phe Val His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr
OO

OS

1O

Ala Val Cys Ala Lieu Ala Ala Lieu. Thir Cys Phe Val Ile Arg Phe Ala
15

2O

25

Lys Asn Cys Met Ser Trp Arg Tyr Ala Cys Thr Arg Tyr Thr Asn Phe
3O

35

4O

Lieu. Lieu. Asp Thir Lys Gly Arg Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

SO

55

160

le Glu Lys Arg Gly Llys Val Glu Val Glu Gly His Lieu. Ile Asp Lieu
65

70

7s

Lys Arg Val Val Lieu. Asp Gly Ser Val Ala Thr Pro Ile Thir Arg Val
Ser Ala Glu Gln Trp Gly Arg Pro
95

2 OO
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<210

SEQ ID NO 12

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 12

Met Lieu. Gly Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Glin Lieu. Lieu. Phe
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Ser Cys Phe Val Ala Lieu Val Ser Ala Asn
2O

25

3O

Gly Asn. Ser Gly Ser Asn Lieu. Glin Lieu. Ile Tyr Asn Lieu. Thir Lieu. Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu Ala Asn Llys Phe Asp Trp Ala Val
SO

55

6O

Glu Cys Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Gly Lieu Val Thr Val
85

9O

95

Ser Thr Ala Gly Phe Val His Gly Arg Tyr Val Lieu Ser Ser Met Tyr
OO

OS

1O

Ala Val Cys Ala Lieu Ala Ala Lieu. Ile Cys Phe Val Ile Arg Lieu Ala
15

2O

25

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
3O

35

4O

Lieu. Lieu. Asp Thr Lys Gly Arg Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
45

SO

55

160

le Glu Lys Arg Gly Llys Val Glu Val Glu Gly His Lieu. Ile Asp Lieu
65

70

7s

Lys Arg Val Val Lieu. Asp Gly Ser Ala Ala Thr Pro Val Thir Arg Val
Ser Ala Glu Gln Trp Ser Arg Pro
95

<210

2 OO

SEQ ID NO 13

<211 LENGTH: 2OO
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 13

Met Lieu. Glu Lys Cys Lieu. Thir Ala Gly Cys Cys Ser Glin Lieu. Lieu. Ser
1.

5

1O

15

Lieu. Trp Cys Ile Val Pro Phe Cys Phe Ala Val Lieu Ala Asn Ala Ser
2O

25

3O

Asn Asp Ser Ser Ser His Lieu. Glin Lieu. Ile Tyr Asn Lieu. Thir Lieu. Cys
35

4O

45

Glu Lieu. Asn Gly Thr Asp Trp Lieu Ala Asn Llys Phe Asp Trp Ala Val
SO

55

6O

Glu Ser Phe Val Ile Phe Pro Val Lieu. Thr His Ile Val Ser Tyr Gly
65

70

7s

8O

Ala Lieu. Thir Thr Ser His Phe Lieu. Asp Thr Val Ala Leu Val Thr Val
85

9O

95

Ser Thr Ala Gly Phe Val His Gly Arg Tyr Val Lieu Ser Ser Ile Tyr
1 OO

105

11O

Ala Val Cys Ala Lieu Ala Ala Lieu. Thir Cys Phe Val Ile Arg Phe Ala
115

12O

125
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Lys

Asn

Cys

Met Ser

13 O

Trp Arg Tyr Ala Cys Thir Arg Tyr Thr Asn Phe
135

14 O

Lieu. Lieu. Asp Thr Lys Gly Gly Lieu. Tyr Arg Trp Arg Ser Pro Val Ile
145

150

Ile Glu

155

160

Lys Arg Gly Lys Wall Glu Wall Glu Gly His Lieu. Ile Asp

1.65

17O

Lys Arg Wall Wall Lieu. Asp Gly
18O

185

Ser Ala Glu
195

Luell

17s

Gln Trp Gly Arg

Ser Wall Ala Thir
190

Pro Ile Thr Arg

Wall

Pro

2 OO

D NO 14
H: 2OO
PRT
SM: Porc ine

reproductive and respiratory syndrome virus

SS

RE:

KEY: misc feature
ON: (34) . . (34)
Ca

loe any

naturally occurring amino acid

Ca

loe any

naturally occurring amino acid

Ca

loe any

naturally occurring amino acid

Ca

loe any

naturally occurring amino acid

Thir Ala

Gly Cys

Phe

Phe Ala Ala Lell Wall Asn Ala Ser

NFORMAT ON: Xaa
RE:

KEY: misc feature
ON: (58) ... (58)
NFORMAT ON: Xaa
RE:

KEY: misc feature
ON: (94) ... (94)
NFORMAT ON: Xaa
RE:

KEY: misc feature

ON: (164 ) . . (164)
&223> OTHER

<4 OO

NFORMAT ON: Xaa

SEQUENCE: 14

Met Leu Gly Lys Cys
1.

Lel

Ser Glin Luell Pro Phe
15

5

Lell
2O

Trp Cys Ile Wall
25

3O

Asn Xaa Ser Ser Ser His Lell Glin Luell Ile Tyr Asn Lell Thir
35
4O
45

Glu Luell Asn

Gly Thr Asp Trp

SO

Luell Asn Xaa

55

Ile

Lys Phe Asp Trp Ala Wall
6O

Glu Thir Phe Wall Ile Phe Pro Wall Luell Thir His Ile Wall Ser

Gly

65

8O

70

7s

Ala Luell Thir Thir Ser His Phe Luell
85

Asp

Thir Wall

9O

Lell Xaa Thir Wall

95

Ser Thir Ala
OO

Gly Tyr yr His Gly Arg

Ala Wall

Ala Lieu. Ala Ala Luell Ile

OS

15

Gly

Wall Lell Ser Ser Ile
1O

Wall Ile

Arg

Ser

Arg

Thir Asn Phe

Tyr

Arg

Ser Pro Wall Ile
160

Luell Ala

2O
Asn

Met Ser

rp Arg
35

Lell Luell
45

Thr Lys

Lys

le Glu

Xaa Gly

Wall Glu Wall Glu

His Lell Ile Asp Luell

Gly

Pro Wall Thir

Luell

65

Arg Wall Wall Lieu.
Ala Glu

Gln Trp Gly Arg
2 OO

Ser Ala Ala

Pro

Arg Wall
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<210

SEQ ID NO 15

<211 LENGTH: 2O1
&212> TYPE: PRT

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 15

Met Arg Cys Ser His Lys Lieu. Gly Arg Phe Lieu. Thr Pro His Ser Cys
1.

5

1O

15

Phe Trp Trp Leu Phe Leu Lleu. Cys Thr Gly Lieu Ser Trp Ser Phe Ala
2O

25

3O

Asp Gly Asn Gly Asp Ser Ser Thr Tyr Glin Tyr Ile Tyr Asn Lieu. Thr
35

4O

45

Ile Cys Glu Lieu. Asn Gly Thr Asp Trp Leu Ser Ser His Phe Gly Trp
SO

55

6O

Ala Val Glu Thr Phe Val Lieu. Tyr Pro Val Ala Thr His Ile Leu Ser
65

70

7s

8O

Lieu. Gly Phe Lieu. Thir Thr Ser His Phe Phe Asp Ala Lieu. Gly Lieu. Gly
85

9O

95

Ala Val Ser Thr Ala Gly Phe Val Gly Gly Arg Tyr Val Lieu. Cys Ser
OO

OS

1O

Val Tyr Gly Ala Cys Ala Phe Ala Ala Phe Val Cys Phe Val Ile Arg
15

2O

25

Ala Ala Lys Asn. Cys Met Ala Cys Arg Tyr Ala Arg Thr Arg Phe Thr
3O

35

4O

ASn Phe Ile Val Asp Asp Arg Gly Arg Val His Arg Trp Llys Ser Pro
45

SO

55

160

le Val Val Glu Lys Lieu. Gly Lys Ala Glu Val Asp Gly Asn Lieu Val
65

70

7s

Thir Ile Llys His Val Val Lieu. Glu Gly Wall Lys Ala Glin Pro Lieu. Thir
8O

85

90

Arg Thir Ser Ala Glu Gln Trp Glu Ala
95

<210

2 OO

SEQ ID NO 16

<211 LENGTH: 15414
&212> TYPE: DNA

<213> ORGANISM: Porcine reproductive and respiratory syndrome virus
<4 OO

SEQUENCE: 16

atgacgtata ggtgttggct C tatgc.catg acatttgtat tt Caggagc tigc gaccatt

6O

ggtacagc cc aaaact agct gcacagaalaa CCCCttctg tacagc cct Ctt cagggga

12 O

gcttaggggit ctdtcc ctag caccittgctt coggagttgc actgctttac gigt ct ct coa

18O

accctittaac catgtctggg at acttgatc ggtgcacgtg Caccc.ccaat gcc agggtgt

24 O

titatggcgga gggccaagttc tactgcacac gatgtct cag tic acggtct Ctcct tcct c

3OO

tgaatctoca agttcCtgag Cttggagtgc tigggcctatt ttacaggc.cc galaga.gc.cac

360

tccggtggac gttgcc acgt gcatt cocca Ctgttgagtg Ctcc.ccc.gcc ggggcctgct

42O

ggctttctgc gat ctitt.cca attgcacgaa taccagtgg aaacctgaac tittcaacaaa

48O

gaatggtgcg ggtcgcagct gagatttaca gagc.cggcca gct cacc cct gcagt cttga

54 O

aggctic taca agtttatgaa cqgggttgcc gctgg taccc tatagt cqga Cctgtc.cctg

6OO

gagtggcc.gt ttittgccaac tocct acatg tagtgataa acctttc.ccg ggagcaactic

660

atgtgctaac caacct gcca citccc.gcaga gqcctaagcc tdaag actitt togc ccttittg

72 O

US 7,608,272 B2
79

80
- Continued

&212> TYPE: DNA

<213> ORGANISM: synthetic
<4 OO

SEQUENCE: 26

gtcggcc.gcg acttacct tt agag

24
10

What is claimed is:

1. A composition comprising a polynucleotide encoding a
hypoglycosylated North American PRRSV GP5 polypeptide
variant wherein at least one N-linked glycosylation site cor
responding to asparagine 51 in a reference GP5 protein of
SEQID NO: 1 is inactivated by mutation, and a therapeuti
cally acceptable carrier.
2. The composition of claim 1, wherein said polynucle
otide comprises an infectious North American PRRSV RNA

15

Vector.

molecule.

3. The composition of claim 1, wherein said polynucle
otide comprises a DNA molecule that encodes an infectious
North American PRRSV RNA molecule.

4. The composition of claim 1, wherein said polynucle
otide comprises a DNA molecule wherein a promoter active
in mammalian cells is operably linked to said polynucleotide
encoding said hypoglycosylated North American PRRSV
GP5 polypeptide variant.
5. The composition of claim 4, wherein said promoter is a
CMV promoter.
6. The composition of claim 1, wherein said N-linked
glycosylation site is inactivated by replacing a codon encod
ing said asparagine 51 with a codon encoding an amino acid
other than asparagine.
7. The composition of claim 6, wherein said codon encod
ing an amino acid other thanasparagine encodes analanine or
a glutamine residue.
8. The composition of claim 1, wherein said polynucle
otide encodes a hypoglycosylated North American PRRSV
GP5 polypeptide variant protein wherein both of said
N-linked glycosylation sites corresponding to asparagine 34
and asparagine 51 in a North American reference GP5 protein
of SEQID NO:1 are inactivated.
9. The composition of claim 8, wherein both of said
N-linked glycosylation sites are inactivated by replacing
codons encoding said asparagine 34 and said asparagine 51
with codons encoding an amino acid other than asparagine.
10. The composition of claim 9, wherein said codons
encoding another amino acid encode either an alanine or a
glutamine residue.
11. The composition of claim 8, wherein one of said
N-linked glycosylation sites is inactivated by replacing one
codon encoding said asparagine 34 or said asparagine 51 with
a codon encoding an amino acid other than asparagine.
12. The composition of claim 1, wherein said therapeuti
cally acceptable carrier is selected from the group consisting
of a protein, a buffer, a surfactant, and a polyethylene glycol
polymer, or any combination thereof.
13. The composition of claim 1, wherein said composition
further comprises at least one adjuvant.
14. The composition of claim 13, wherein said adjuvant is
selected from the group consisting of aluminum hydroxide,
Quil A, an alumina gel Suspension, mineral oils, glycerides,
fatty acids, fatty acid by-products, mycobacteria, and CpG
oligodeoxynucleotides, or any combination thereof.
15. The composition of claim 13, wherein said composi
tion further comprises a second adjuvant is selected from the

group consisting of interleukin 1 (IL-1). IL-2, IL4, IL-5, IL6.
IL-12, gamma interferon (g-IFN), cell necrosis factor, MDP
(muramyl dipeptide), immuno stimulant complex (ISCOM),
and liposomes.
16. The composition of claim 1, wherein said polynucle
otide comprises a viral vector selected from the group con
sisting of a vaccinia virus vector, a herpes simplex viral vec
tor, an adenovirus vector, an alphavirus vector, and a TGEV

25
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17. An isolated polynucleotide encoding a hypoglycosy
lated North American PRRSV GP5 polypeptide variant
wherein at least one N-linked glycosylation site correspond
ing to asparagine 51 in a reference GP5 protein of SEQ ID
NO:1 is inactivated by mutation.
18. The isolated polynucleotide of claim 17, wherein both
N-linked glycosylation sites corresponding to asparagine 34
and asparagine 51 in SEQID NO:1 are inactivated.
19. The isolated polynucleotide of claim 17, wherein said
polynucleotide comprises an infectious North American
PRRSV RNA molecule.

20. The isolated polynucleotide of claim 17, wherein said
polynucleotide comprises a DNA molecule that encodes an
infectious North American PRRSV RNA molecule.
35

40
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21. The isolated polynucleotide of claim 17, wherein said
polynucleotide comprises a DNA molecule wherein a pro
moter active in mammalian cells is operably linked to said
polynucleotide encoding said hypoglycosylated North
American PRRSV GP5 polypeptide variant.
22. The isolated polynucleotide of claim 21, wherein said
promoter is a CMV promoter.
23. The isolated polynucleotide of claim 17, wherein said
N-linked glycosylation site corresponding to asparagine 51 is
inactivated by replacing a codon encoding said asparagine 51
with a codon encoding an amino acid other than asparagine.
24. The isolated polynucleotide of claim 23, wherein said
codon encoding another amino acid encodes an alanine or a
glutamine residue.
25. The isolated polynucleotide of claim 17, wherein an
N-linked glycosylation site corresponding to asparagine 34 in
a reference GP5 protein of SEQID NO:1 is inactivated.
26. The isolated polynucleotide of claim 25, by replacing a
codon encoding said asparagine 34 with a codon encoding an
amino acid other than asparagine.
27. The isolated polynucleotide of claim 25, wherein said
codon encoding another amino acid encodes an alanine or a
glutamine residue.
28. The isolated polynucleotide of claim 25, wherein one of
said N-linked glycosylation sites is inactivated by replacing
one codon encoding said asparagine 34 or said asparagine 51
with a codon encoding an amino acid other than asparagine.
29. The isolated polynucleotide of claim 17, wherein said
polynucleotide comprises a viral vector selected from the
group consisting of a vaccinia virus vector, a herpes simplex
viral vector, an adenovirus vector, an alphavirus vector and a
TGEV vector.

